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ABSTRACT 
Extracellular vesicles (EVs) are nanometer-sized, lipid membrane enclosed, vesicles that are 
secreted by most, if not all, cells and contain macromolecular material of the source cell 
including lipids, proteins and various nucleic acid species. Over the last two decades, EVs 
have been recognized as important mediators of cell-to-cell communication that influence 
both physiological and pathological conditions. Owing to their ability to transfer bioactive 
components and surpass biological barriers, EVs are increasingly explored as therapeutics, 
both as natural delivery vectors and in its own right, as improved cell based therapies. 
In paper I, the great potential of EVs as therapeutic entities is explored by equipping EVs 
with the brain targeting rabies viral glycoprotein peptide and load them with siRNA against 
alpha-synuclein (a-Syn). The findings demonstrate that EVs efficiently deliver the siRNA to 
the target with subsequent reduction of a-Syn pathology in vitro as well as in the brains of a-
Syn overexpressing transgenic mice. Thus, this indicates that targeted EVs can be employed 
as efficient vectors for siRNA therapy against Parkinson’s disease and other a-Syn related 
pathological conditions. 
In pursuance of using EVs for therapeutic purposes, the fate of injected EVs must be 
understood. Consequently, the aim of paper II was to elucidate the biodistribution of injected 
EVs and to investigate factors that may influence the tissue distribution of exogenous EVs. 
The use of the fluorescent lipophilic dye DiR was thoroughly assessed and found to be a 
suitable labelling method for biodistribution studies that allowed for in vivo EV tracing with 
high sensitivity. EVs displayed a general distribution pattern with high accumulation in liver, 
lung and spleen, which is in line with previous findings of mononuclear phagocyte system 
(MPS)-associated EV uptake. In addition, the biodistribution profile of EVs was, to a varying 
degree, influenced by the administration route, cell source, dosing and targeting. These 
variables may thus be adopted for future EV-based therapies to reflect the preferred 
biodistribution and/or pharmacokinetic profile for a given therapeutic approach.  
Furthermore, EVs have been found to convey the beneficial immunomodulatory effects of 
mesenchymal stromal cell (MSC)-based cell therapy. Based on these findings and studies 
demonstrating that EVs can be engineered to display surface moieties, the objective of paper 
III was to produce MSC-derived EVs that express therapeutic proteins. A chimeric construct, 
with an EV sorting domain fused to a non-signalling cytokine receptor, was introduced to the 
parental cell to produce EVs that can sequester cytokines, termed decoy EVs. By targeting 
the central inflammatory pathways of TNFa and IL-6 trans-signalling, these decoy EVs 
significantly ameliorate systemic inflammation and neuroinflammation in vivo. This novel 
concept thus combines the beneficial effects of stem cell therapy, EVs as delivery agents and 
cytokine targeted biologics.  
Taken together, the findings in this thesis suggest that EVs have the potential to be utilized as 
a future platform of highly potent multifaceted biopharmaceuticals. 
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1 INTRODUCTION 
1.1 HISTORY OF EXTRACELLULAR VESICLES 
Extracellular vesicles (EVs) hold great potential to be the next medical breakthrough as an 
emerging platform of highly potent and multifaceted biopharmaceuticals. The EV research 
field has grown almost exponentially in terms of the number of published scientific articles 
over the last decades, which has led to an increased understanding of EVs’ biogenesis, 
content and biological function. Figure 1 shows the number of published articles over time 
and highlights the breakthrough findings, publications and events of the field.  
 
 
Figure 1 – Background graph showing number of published articles per year on PubMed with the search term 
“extra cellular vesicles”. Important breakthrough articles are indicated by numbers (1-7) over time [1-9]. 
 
Extracellular vesicles include plasma membrane shed vesicles, such as microvesicles and 
apoptotic vesicles, as well as exosomes, which are derived from the endosomal pathway (see 
classification below) [10]. The field of EV research springs from the findings on coagulation 
from the 1940-50s, where it was discovered that even platelet-free plasma possesses a small 
coagulation component that can be sedimented. In an article published in 1964, Peter Wolf 
coined the term “platelet dust” to describe this small plasma component originating from 
platelets and pelleted down by high-speed centrifugation, which could be identified by 
electron microscopy and was later defined as EVs [1]. Furthermore, studies and findings of 
cellular compartments including the endosome and lysosome, which were granted the 1974 
Nobel prize in Medicine to Albert Claude, Christian de Duve, and George E. Palade, serve as 
the fundamental basis for understanding the biogenesis of exosomes.  In 1983 two groups 
described formation and secretion of exosomes while investigating the transferrin recycling 
cycle [2, 3]. Those groups showed that labelled transferrin was internalized, redistributed via 
endosomes to a multivesicular compartment and later externalized via vesicles, thus partially 
describing what was later identified as EVs.  
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The initial hypothesis was that EVs carried cellular waste and served as a disposal bin to 
maintain cellular homeostasis. However, about two decades ago, Raposo et. al. presented the 
first evidence that EVs have other important biological functions. The groundbreaking article 
“B Lymphocytes Secrete Antigen-presenting Vesicles”, published in 1996, showed that EVs 
derived from B lymphocytes can induce an immune response [4]. In 1998, Zitvogel et. al. 
published the first therapeutic approach using EVs in Nature Medicine with the title 
“Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-
derived exosomes” [5]. Following these findings, two clinical trials using autologous 
dendritic cell-derived EVs pulsed with tumor antigens were conducted in 2005, for the 
treatment of metastatic melanoma and non-small cell lung cancer, respectively [6, 7]. A 
decade ago, in 2007, the importance of EVs was further appreciated through a study by 
Valadi et. al. published in Nature Cell Biology, which was the next groundbreaking study 
showing that EVs take part in cell-to-cell communication and that EVs can deliver functional 
mRNA and miRNA to recipient cells [8]. Another pioneering development was published in 
2011 by Alvarez-Erviti et al, showing that engineered EVs can be targeted to the brain and 
used for delivery of functional siRNA [9]. This important article highlights the great potential 
of EVs as natural delivery vectors for therapeutics. 
1.2 CLASSIFICATION 
The term extracellular vesicles is a hypernym covering different classes of vesicles derived 
from eukaryotic and prokaryotic cells. EVs are enclosed by a lipid bilayer, with a size ranging 
from 30-2,000 nm in diameter and contain proteins, lipids and nucleic acids originating from 
the source cell [10]. Still being in its youth, the EV field has had somewhat inconsistent 
nomenclature where the terms microparticles, microvesicles, exosomes, and EVs have been 
used interchangeably to describe vesicles derived from cells. Others have used terms based 
on the origin of the vesicles, such as platelet dust [1] (platelet-derived vesicles), prostasomes 
[11] (derived from prostate epithelium) and dexosome [7] (dendritic cell released vesicles), 
etc. The most common definition of the different classes of EVs is based on biogenesis, 
density, size, and/or differential centrifugation properties, i.e. the required gravitational force 
for pelleting [12]. Here, I am following the suggestions by Gould and Raposo, whom 
recommend the term EVs to cover the different forms of cell-derived vesicles and to define 
the denominations used to describe different vesicles [12]. Furthermore, I am employing the 
definitions of the classes of EVs based on their biogenesis as described by EL Andaloussi et. 
al. [10], which states that there are three main classes: exosomes, microvesicles and apoptotic 
bodies. The most studied type of EVs is exosomes, which are formed through the endosomal 
system, with a size of about 40-120 nm in diameter. Microvesicles are more heterogeneous 
with sizes ranging between 50-1000 nm and derive from the direct outward budding of the 
plasma membrane. Similar to microvesicles, apoptotic bodies are shed directly from the cell 
membrane and are larger in size, measuring 500-2000 nm in diameter, but are formed by 
blebbing of apoptotic cells and may contain diverse parts of the dying cell source. As 
mentioned by EL Andaloussi et. al [10] and emphasized by van der Pol et. al. [13] as well as 
Witwer et. al. [14], there is an overlap between the different EV classes in terms of size, 
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density and protein content. This heterogeneity has further been strengthened by findings of 
exosome subpopulations, indicating that some exosomes may contain only certain exosome 
characteristics but lack others [15]. Despite the muddled nomenclature, basic requirements 
have been established within the EV-community [16]. In this work, the focus lays on the EV 
types commonly classified as exosomes and smaller microvesicles, but as discussed above 
the distinction between the classes are still unclear and hence the term EV will be used 
subsequently.     
 
1.3 BIOGENESIS OF EXTRACELLULAR VESICLES 
EVs are formed either as exosomes from the endocytic pathway where invagination of the 
endosomal membrane forms multivesicular bodies (MVBs) that can fuse with the plasma 
membrane to release exosomes into the extracellular milieu. MVs, on the other hand, arise 
from the outward budding and fission of the plasma membrane [10, 17, 18]. Apoptotic 
bodies, which will not be further emphasized in this work, are formed by blebbing of 
apoptotic cells [10]. An overview of the biogenesis is illustrated in Figure 2.   
1.3.1 MVB Formation 
The endosomal system comprises early to late endosomes, MVBs and recycling endosomes 
and act as a sorting network that direct various intraluminal vesicles to appropriate 
destination, including lysosomal degradation, cellular recycling or exocytosis [19-21]. After 
deposition of content destined for recycling into recycling endosomes, the early endosomes 
transform into late endosomes. During this maturation, inward budding of the endosomal 
membrane occurs, giving rise to intraluminal vesicles (ILVs) and subsequent formation of the 
MVB [20, 22, 23]. The main process governing the creation of ILVs and the maturation of 
the late endosome into MVB is through the endosomal sorting complex required for transport 
(ESCRT), consisting of four protein complexes known as ESCRT-0, -I, -II, -III, which are 
recruited to the site of ILV formation [24-26]. Ubiquitinated proteins on the cytosolic side of 
the endosome, presence of phosphatidylinositol 3-phosphate (PIP3), which is abundant on 
early endosomes, and membrane curvature have all been shown to play a role in the 
recruitment of ESCRT-0, -I and –II [27]. These ESCRTs are believed to initiate the 
intraluminal membrane budding by binding and sequestering ubiquitinated proteins, whereas 
ESCRT-III completes this process through membrane fission and abscission of ILVs. 
ESCRT-III becomes associated via ALG-2-interacting protein X (ALIX) that simultaneously 
binds tumor susceptibility gene 101 (TSG101), which is part of the ESCRT-1 complex, and 
charged multivesicular body protein 4 (CHMP4), which is included in ESCRT-III [28, 29]. 
Furthermore, different ESCRT-independent pathways have been identified and cells with 
inactivated ESCRTs can still form MVBs [30-33]. Other pathways that act in parallel to, or 
cooperate with, the ESCRT system include ceramide-dependent ILV formation and 
enrichment of membrane proteins, known as tetraspanins. The sphingolipid ceramide, which 
is present in exosomes, has in some settings, been shown to facilitate the invagination of 
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ILVs, possibly by its cone-shaped configuration [34]. Trajkovic et. al. showed that inhibition 
of neutral sphingomyelinase, an enzyme necessary for ceramide production, decreases the 
yield of exosomes. In addition, clustered enrichment on the endosome membrane of 
tetraspanins, such as CD63 and CD9, which are commonly found in exosomes, is believed to 
initiate the formation of ILVs via specific protein-protein interactions [20]. 
1.3.2 Formation of Exosomes 
The formation of MVBs with the invagination of ILVs constitutes the start of exosome 
biogenesis. [21]. MVBs and their content are either directed to the lysosome for degradation 
or toward fusion with the plasma membrane and subsequent release of the ILVs that now 
become exosomes as they enter into the extracellular milieu [20]. The process that dictates 
the fate of MVB to either fuse with the lysosome or the plasma membrane is still being 
dissected [35]. It has been proposed that endosomes are being directed to the different fates 
by a series of different Rab GTPases. The members of the Rab GTPase family display 
distinct intracellular membrane localization patterns and regulate membrane traffic between 
organelles, including vesicle movement along actin and tubulin networks, and are also 
associated with the formation of vesicles and membrane fusion [35-39]. For instance, late 
endosomes have distinct RAB7 and RAB9 membrane domains that guide them towards 
lysosmal degradation via the RAB7 effector Rab-interacting lysosomal protein (RILP) or 
towards plasma membrane fusion via RAB9 and TIP47 association [40-43]. In addition, 
differences in cholesterol levels of MVBs have been shown to govern the direction towards 
plasma membrane or lysosome fusion, where cholesterol enriched MVBs have been shown to 
be destined for membrane fusion and vice versa [44]. The Rab GTPases have further been 
indicated to play an important role in the MVB to plasma membrane-fusion and release of 
exosomes. Suppression of RAB11, RAB27a, RAB27b and RAB35 or their effector proteins 
have all been demonstrated to negatively affect exosome release [21, 45-47]. It has 
furthermore been suggested that there is an association of Rab GTPases and soluble N-
ethylmaleimide-sensitive factor attachment protein receptors (SNARE) complexes [48-51], 
which are known to be involved in membrane fusion events [52, 53]. More specifically, a 
SNARE protein known as vesicle-associated membrane protein 7 (VAMP7), has been 
demonstrated to take part in the release of exosomes [54]. In conclusion, several modes of 
action have been proposed for exosome biogenesis and release and it is likely that several 
mechanisms operate in parallel, which makes the study of these cellular events rather 
intricate.  
1.3.3 Biogenesis of Microvesicles 
Microvesicles (MVs) arise from a completely different pathway which – as compared to 
exosome biogenesis – is even less well characterized. MV formation comes about from 
outward budding and fission of the plasma membrane, which is believed to be accomplished 
by a combination of mechanisms including phospholipid rearrangement and activation of 
cytoskeletal proteins. Phospholipids and proteins are non-uniformly distributed within the 
plasma membrane. The heterogeneous distribution and formation of clusters is regulated by 
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scramblases, flippases and floppases, which are aminophospholipid translocases that transfer 
phospholipids between the outer and the inner leaflet and vice versa [55-57]. The initiating 
step of the MV biogenesis has been suggested to emanate from surface exposure of 
phosphatidylserine (PS) by translocation to the outer leaflet [20, 58-60]. Others have shown 
that increased calcium levels trigger redistribution of phospholipids, which results in MV 
release [61, 62].  
Following phospholipid redistribution, the budding process is completed by cytoskeletal 
protein contraction, through actin–myosin interactions. The cytoskeletal contraction has been 
demonstrated to be initiated by a signaling cascade starting with ADP-ribosylation factor 6 
(ARF6) that activates phospholipase D (PLD), which leads to activation of myosin light chain 
via recruitment of extracellular signal-regulated kinase (ERK) that phosphorylates myosin 
light-chain kinase (MLCK) [21, 63].  
The involvement of TSG101, the ESCRT-1 component, which has been associated with 
exosomal biogenesis, as described above, has also been connected to MV biogenesis [64, 65]. 
Here, however, TSG101 is believed to interact with a tetrapeptide protein within the Arrestin 
1 domain–containing protein 1 as part of MV formation. Furthermore, in addition to calcium, 
external factors, such as hypoxia, have been shown to induce MV release via another 
pathway associated to the expression of the small GTPase RAB22A that co-localizes with 
materializing MVs at the plasma membrane [66].  
In summary, the distinct difference between exosome biogenesis, via the endocytic pathway, 
and MV formation, through membrane budding and fission, is well established. However, the 
detailed processes of vesicle biogenesis are still not fully understood and the studies are, to 
some extent, hampered by downstream processes and analytics, including the first step that 
involves isolating and purifying the formed EVs from the extracellular milieu in an accurate 
manner.  
 
1.4 ISOLATION OF EXTRACELLULAR VESICLES  
EVs have been successfully isolated from conditioned cell culture media [4, 67, 68] and 
various body fluids, including blood serum [69, 70] and plasma [71, 72], urine [73, 74], 
semen [75, 76], breast milk [77], cerebrospinal fluid [78, 79], amniotic fluid [80], ascites fluid 
[81, 82], bile [83] and saliva [84]. Isolating EVs is technically challenging due to their small 
size, heterogeneity, physiochemical properties and often complex surroundings. There are a 
number of different considerations that needs to be taken into account when assessing the 
isolation procedure and the purified EV sample. The optimal isolation technique should give; 
1) high recovery of EVs that are 2) pure, i.e. not contaminated by non-vesicular components 
and 3) have intact integrity and biochemical properties. 
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1.4.1 Technical Considerations of Different Isolation Methods 
The currently considered gold standard isolation technique in the field, differential 
centrifugation with ultracentrifugation (UC) [4, 85] is limited by low EV recovery, risk of co-
sedimentation of non-vesicular macromolecule contaminants, and EV integrity disruption. 
Furthermore, UC is laborious and time-consuming with limited scalability. It is also 
associated with EV aggregation due to high gravitational forces [86-89]. Various alternative 
isolation techniques have consequently been explored to improve the isolation process. These 
isolation methods can be grouped into categories that include UC, density gradient separation 
[90, 91], filtration with or without size exclusion based techniques [87, 92, 93], precipitation 
[94, 95], affinity binding techniques [96, 97] and microfluidics [98, 99].  
1.4.1.1 Differential centrifugation with ultracentrifugation (UC) 
The classical differential centrifugation process involves a series of increasing centrifugation 
steps that start with a 300-500 x g spin followed by a 2,000 x g spin to remove floating cells 
and cell debris. The supernatant is then spun at 10,000 x g to pellet larger EVs. This fraction 
is sometimes referred to as the MV pellet or simply the 10,000 x g EV pellet. This is often 
followed, or replaced, by a sterile 0.2 µm filtration to enrich for smaller EVs, followed by an 
UC step of about 100,000 x g to pellet the small EVs. The UC step is usually repeated after 
re-suspending the pellet, to increase the purity [85]. Numerous different protocols using 
different speeds, centrifugation times, and rotors have been employed for the differential 
centrifugation process. The inconsistency of EV isolation within the field consequently 
hampers comparability of the findings between different publications with varying 
centrifugation based-isolation protocols. In fact, comparison of different factors of this 
process, including EV media viscosity, UC speed, rotor type and angle, etc., has been 
investigated in order to reach a consensus of a defined isolation protocol using differential 
centrifugation [85, 100, 101]. In order to overcome the contamination of non-vesicular 
components in the isolated EV pellet of the differential centrifugation process, an additional 
step using density gradient to separate the EVs based on their buoyancy, can be employed. 
Density gradient separation effectively reduces non-EV-associated protein contamination [85, 
102]. However, if the EV medium is more complex than cell culture conditioned media, other 
contaminants with similar density, such as lipoprotein particles in blood plasma, will remain 
[103].    
1.4.1.2 Filtration and/or size exclusion based techniques 
In contrast to density-based isolation techniques, size-based isolation techniques are being 
increasingly employed for EV isolation. Ultrafiltration devices [104], as well as tangential 
flow filtration (TFF) systems [105], have been used for isolating and concentrating the EV 
fraction of cell culture conditioned media based on EV size. In order to purify the EVs from 
co-isolated contaminants a subsequent step is typically added using size exclusion 
chromatograph (SEC), which separates smaller molecules, by transiently trapping them in 
pores of a matrix, from larger molecules [72, 87]. Of note, the addition of SEC has been 
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shown to be associated with improved EV integrity and protein purity as compared to UC-
based isolation [87]. Small commercial SEC columns specialized for EV isolation are now 
available and are used in numerous labs. These are suitable for isolations from relatively 
small volumes of EV containing media, such as blood plasma, but are not very scalable per 
se. Further developments of SEC include combining size exclusion with bind-elute 
chromatography, which, when combined with a filtration step, has been shown suitable for 
scalable EV isolation [106]. 
1.4.1.3 Precipitation methods 
Polymer-based precipitation methods include commercial isolation kits, such as ExoQuickTM 
and Total Exosome IsolationTM as well as Polyethylene glycol (PEG)-precipitation that has 
been adopted for EV isolation and also applied in clinical settings [95]. Precipitation methods 
have been widely used and demonstrate high recovery of EVs, however the purity is often 
reported to be rather low with co-precipitation of non-vesicular-associated protein and nucleic 
acid contaminants that may render invalid conclusions of EV content and function [107]. 
1.4.1.4 Affinity binding techniques 
Other techniques, such as affinity-based capture, utilize known EV composition properties. 
For instance, immuno-affinity capture by anti-EpCAM and anti-CD63 antibodies, have been 
used for small EV isolation with high purity [65, 108]. This isolation method will naturally 
favor EVs with high expression of these EV antigens, resulting in partial EV isolation, which 
may or may not be advantageous depending on the research approach. In addition, the 
capturing beads or antibodies may interfere with down-stream analysis. To overcome this, 
another affinity based approach targets phosphatidylserine, which is exposed on the EV 
surface, using a calcium dependent binding to a transmembrane protein (T cell 
immunoglobulin and mucin domain protein 4, Tim4) decorated on magnetic beads. By 
adding calcium chelating buffer the captured EVs are released from the beads [109].   
1.4.1.5 Microfluidics 
Microfluidic methods are another attractive group of EV isolation approaches applicable for 
small scale isolation and high throughput screening of e.g. body fluid samples for diagnostics. 
Several different microfluidic techniques, sometimes referred to as lab-on-chip devices, 
including dielectrophoresis, immune-affinity, hydrodynamic based methods and magnetic-
based techniques have been used for EV isolation [86, 110].  
The large variety of emerging EV isolation techniques with different pros and cons, and the 
lack of in the field as to which method to use, may result in an increased risk of 
incomparability. In addition, co-isolation of contaminants including proteins and nucleic 
acids may result in invalid conclusions of EV content and function. However, the variety of 
techniques also provides researchers the ability to cherry-pick the isolation method most 
suitable for their application and down-stream analysis.  
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1.4.2 Clinical Grade Production of EVs 
A large share of EV research is devoted to exploring EVs as therapeutic moieties in a number 
of applications, as discussed below. For therapeutic purposes, EVs are usually isolated from 
cell culture conditioned media of a producer cell source with less complexity as compared to 
body fluids. There are however other challenges to consider. Transitioning EV isolation from 
in vitro settings and small preclinical studies to clinical settings does not only require a great 
deal of scalability, high purity, retained integrity and functionality, but also clearly defined 
components, standard operation procedures for reproducibility, and sterility. A recent position 
article suggests that the following must be considered for clinical grade production of EVs 
[89]: 
• Isolation techniques and standardization 
• Purity and impurities 
• Scalability of technology 
• Adequate quality of reagents and materials 
• In-process controls     
The isolation techniques used for EV application in clinical settings until now are 
ultracentrifugation into a sucrose cushion with a preceding concentration step of the 
conditioned media using ultrafiltration [6, 7, 111, 112] or purification using PEG-based 
precipitation [95]. Following the advances made in EV isolation techniques, future clinical 
trials will most probably require a greater scalability of isolation and an increased level of 
purity. It appears likely that a combinational approach, utilizing the advantage of different 
isolation techniques, would be preferable. Currently, filtration based isolation techniques, e.g. 
TFF, in combination with SEC seem to be very promising for clinical application, owing to 
high scalability, reproducibility as well as the possibility to be kept in a closed system.         
 
1.5 CHARACTERIZATION OF EXTRACELLULAR VESICLES 
The combination of EVs’ invisibility (by naked eye and light microscopy) and undetectability 
by human senses, with their seemingly remarkable functions and complexity has intrigued a 
whole field of researchers. Naturally, the technical challenges associated with their nanometer 
size range, heterogeneity and often complex environment, are equally well impacting the 
characterization of the isolated EVs. Owing to this, as well as the limitations of isolating 
perfectly pure EV samples and limitations of the analyses, there is no exclusive detection 
technique available and the characterization of EVs requires a combinational approach [16].  
1.5.1 Size Characterization 
Transmission electron microscopy (TEM) was the first technique used to detect EVs and is 
still often included for EV characterization and can be made increasingly EV-specific via 
immunolabelling of vesicular proteins (immuno-EM) [113]. Atomic force microscopy (AFM) 
is an alternative microscopy method suitable to detect EVs [114]. Size distribution 
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measurements, including nanoparticle tracking analysis (NTA), dynamic light scattering 
(DLS) and/or resistive pulse sensing (RPS), are commonly used to assess particle size and 
concentration of a sample. All of the methods have individual shortcomings [115], but they 
also share limitations in specificity as EV sized non-vesicular particles, such as lipid particles 
and protein complexes, may falsely be detected as EVs. Furthermore, as with microscopy 
techniques, these techniques include subjective settings of e.g. light intensity, sample view 
and pre- and post-acquisition detection thresholds, which have an impact on the result and 
may affect the reliability and reproducibility of the measurement. With an awareness of the 
technical limitations and when used in a combinational characterization approach, these 
methods do however contribute with valid and highly important information in EV research.  
1.5.2 Density Characterization 
In parallel to size and content, EVs can also be characterized by density. Exosomes have been 
reported to have a slightly higher buoyant floating density (1.13-1.19 g/ml) [116] compared 
to MVs (1.03-1.08 g/ml) [117] and their density can be assessed using density gradient 
separation based on e.g. layers of different sucrose concentrations [85]. However, risk of 
hyperosmotic pressure from the sucrose affecting the EVs’ properties; high variability of 
measurements depending on sample loading techniques; differences associated with 
centrifugation duration and speed; inconsistencies in protocols used in the field; and inability 
to distinguish from lipoprotein particles and viral particles, have all been reported as issues 
related to sucrose density gradient separation for EVs [15, 85, 118, 119]. An alternative 
density gradient, based on different concentrations of the isosmotic iodixanol (OptiprepTM) 
has been reported to overcome some of these shortcomings [91].     
1.5.3 Content Characterization 
In addition to the morphological features, EVs are also characterized based on their content. 
Similar to the characterization of size, quantity and density, non-EV-associated contaminants 
may give rise to false positive readings with the risk of artefacts being reported as EV 
attributes. This further emphasizes the need for appropriate controls, utilizing adequate 
isolation techniques and an awareness of the limitations in EV purification and 
characterization.   
1.5.3.1 Protein characterization 
Protein content assays are commonly utilized to probe for the presence of known EV-
associated proteins, including tetraspanins such as CD63, CD9 and CD81 as well as 
biogenesis-associated components, e.g. TSG101 and ALIX (see below for protein content of 
EVs). Likewise, detection of non-EV-associated proteins, such as endoplasmic reticulum 
(ER)-associated calnexin, to indicate their absence, is normally assessed. In addition to basic 
molecular biology techniques, such as western blot (WB), which has relatively poor detection 
limit and requires relatively high protein levels, high-throughput mass spectrometry-based 
proteomics for in-depth proteomic analysis of EVs have demonstrated to be highly sensitive 
and able to detect thousands of proteins in an EV sample [87]. For detection of EV surface 
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membrane proteins, antibody coated beads for flow cytometry is increasingly being exploited 
as a versatile and rapid tool for the EV analysis, but does not allow for absolute quantification 
[120, 121].  
1.5.3.2 Nucleic acid characterization 
The presence of nucleic acids is frequently analyzed in EVs, owing to the early findings of 
the ability of EVs to deliver functional RNA [8]. The main focus is on various RNA species, 
which have repeatedly been found in EVs, whereas for instance the presence of DNA is still 
debatable [122]. RNA detection is carried out using molecular biology techniques, such as 
quantitative polymerase chain reaction (qPCR), northern blotting, microarrays and next 
generation sequencing. Again, contaminating non-EV-associated RNA, such as extracellular 
RNA protein complexes or lipoprotein complexes, may interfere with the characterization 
[123, 124]. Different attempts to address the risk of contaminants have been made, including 
proteinase and RNase treatments to disrupt ribonucleoproteins outside of EVs. However, 
possible “truly” EV surface associated RNA will then also be disrupted. Furthermore, the 
levels of e.g. miRNA have been reported to be as low as less than one molecule of a given 
miRNA per EV in average and these minute quantities indicate the challenge and need for 
optimized isolation and characterization [125]. The concerns regarding EV-associated RNA 
characterization is being appreciated within the EV field and was in fact the focus of a recent 
position paper from the International Society of Extracellular Vesicles (ISEV) [122]. 
1.5.3.3 Lipid characterization 
A growing part of the EV field is also focusing on the lipid content of EVs, which has been 
somewhat overlooked as compared to the efforts to dissect the protein and nucleic acid 
content. In parallel to the other characterization methods, lipidomics faces the same 
challenges of possible artifacts from non-vesicular impurities. Methods such as high-
throughput mass-spectrometry are used to decipher the lipid repertoire of EVs, which will 
expand our understanding of EVs and most possibly impact on how we exploit EVs as 
therapeutics [126].   
1.5.3.4 Characterization of functionality 
In addition to the characterization of EV morphology and components, integrity and 
functionality assessments are highly important for understanding the impact of isolation and 
storage methods as well as to explore EV biology and applying EVs as therapeutics. The 
stability of EVs is often indicated as an advantage for exploiting EVs as drug-modalities. The 
stability is commonly assessed based on changes over time in regard to size and composition, 
including proteins and RNA, as well as membrane permeability studies measuring the 
presence of the EV components in the sample supernatant. Cellular uptake of the isolated 
EVs, e.g. with a fluorescent label for traceability, is frequently used as a functional readout 
[127-130]. There is however a risk in this system of merely following the free label and the 
functionality is limited to uptake and does not convey insight into the effects of EVs in the 
target cell. A method that recently has been applied for EVs that overcomes some of these 
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limitations is the Cre/LoxP system, where functional delivery of Cre recombinase mRNA or 
protein via EVs can be assessed by Cre-reporter cells, which generate a fluorescent protein 
upon recombination of flanking LoxP sites, both in vitro and in vivo [131, 132]. In addition, 
numerous other functionality readouts based on the studied EV component-specific actions, 
including miRNA, mRNA and protein activity, have been described. Furthermore, functional 
assays based on EV type-specific actions, such as immune stimulation by antigen presenting 
cell (APC)-derived EVs by T-cell activation assays [5, 133] and the immune modulating 
functions of mesenchymal stromal cells (MSC)-derived EVs [134], are used to provide 
evidence for the biological function of EVs.      
1.5.4 Future Characterization Considerations 
The methods currently used for characterization of EVs are mostly based on a bulk EV 
sample and often require relatively high numbers of EVs for analysis. Size distribution 
measurement with NTA or protein detection with WB, for instance, requires about 1x108 – 
1x1010 EVs [115]. As aforementioned, EVs are believed to be relatively heterogeneous with 
different classes and subpopulations. Hence, the individual vesicles in a bulk EV sample, 
purified with current isolation techniques, will differ in both morphology and content. In 
addition, artefacts from contaminants due to insufficient isolation and purification methods, 
as well as buffer-associated artefacts, e.g. EV-sized calcium phosphate aggregates in PBS 
[135], which can interfere with size distribution measurements and quantifications, indicate 
the need for standardized characterization methods.  
Moreover, in order to further understand EV biology as well as for applying EVs as 
therapeutics, there is a need to further dissect the EV bulk sample and move towards single 
vesicle analysis. In addition to immuno-EM, fluorescence correlation spectroscopy (FCS) has 
been used for single vesicle analysis [136]. The main drawback of this is the need of a 
fluorescent tag that is usually introduced by a dye or genetically engineered EV membrane 
proteins with a fluorescent moiety, which limits the detection to EVs with that particular 
moiety. Another method that has gained increased focus is flow cytometry for single EV 
characterization. Regular flow cytometers are not able to detect individual vesicles <300 nm 
[115], however by optimizing acquisition and analysis parameters of configurable flow 
cytometers, single particle analysis of EVs has been reported [137, 138]. It is expected that 
flow cytometry-based systems will offer more robust and enhanced multiparameter analysis 
at a single vesicle level in the near future [89, 139]. 
 
1.6 COMPOSITION OF EXTRACELLULAR VESICLES 
Despite the limitations of current isolation and characterization methods, the composition and 
content of EVs are extensively being unraveled with in-depth nucleic acid characterization, 
preoteomics and lipidomics studies being undertaken. Databases, such as Exocarta, 
Vesiclepedia, and EVpedia, have been generated to compile these comprehensive datasets for 
systematic analysis [140-142]. All subtypes of EVs share a general composition of an outer 
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lipid bilayer and various proteins, lipids and nucleic acids carried by the vesicles, as 
illustrated in Figure 2. The specific content of EVs is however largely dependent on 
biogenesis, cell source and culturing conditions.       
 
 
Figure 2 – Illustration of EV (MVs and exosomes) biogenesis and general EV composition. 
 
1.6.1 Protein Content 
The protein content of EVs is usually utilized as characterization markers of EVs and their 
subtypes. Many of the commonly found proteins are involved in the biogenesis and formation 
of EVs. Exosomes, which are derived from the endocytic pathway, have been shown to 
generally contain proteins associated with their endosomal origin including major 
histocompatibility complex class II (MHC II) and tetraspanins. In addition, ESCRT 
machinery components, such as Alix and TSG101 and chaperone heat shock proteins, such as 
Hsp70 and Hsp90, as well as RAB27A, RAB11B, associated with exosomes biogenesis as 
described above, are all commonly found in exosomes, but may also be present in MVs 
[143]. MVs on the other hand, have been reported to be enriched in glycoprotein Ib, integrins 
and P-selectin [113]. Many of the EV-mediated effects, attributed to various EV-enriched 
proteins, are often parental cell-specific. Examples of this include EV-mediated disposal of 
transferrin receptor via EVs during erythrocyte maturation [2]; MHC II display on the surface 
of EVs derived from APCs, which can elicit immune responses [4]; immune suppression 
mediated by placenta-derived EVs via surface expression of Fas ligand (FasL) and TRAIL, 
which maintain immune-privileged sites [144]; and tumor-associated fibroblasts that shuttle 
the metalloproteinase ADAM10 via EVs, which promotes the motility of breast cancer cells 
[145]. In addition to the common and cell type-specific EV proteins, EVs tend to be devoid of 
proteins associated with non-endosomal intracellular compartments, including mitochondria, 
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Golgi apparatus and ER [146, 147]. Absence of these non-EV-related proteins can thus serve 
as confirmation of EV purity in the EV isolation process [148].   
1.6.2 Lipid Content 
The lipid composition of EVs is essential for the membrane stability, structural rigidity and 
resistance to physiochemical changes [149, 150]. In addition, there is evidence of lipid-
dependent functions in EVs with transfer of bioactive lipids via EVs and the abovementioned 
role of lipids in the biogenesis of EVs [151]. EVs differ in their lipid composition compared 
to their parental cells with an EV-specific enrichment of sphingomyelin, cholesterol, PS and 
glycosphingolipids and a decreased level of phosphatidylcholine and diacyl-glycerol [151], 
which clearly indicates a sorting mechanism. A number of lipids has been found to be 
involved in the formation of EVs. In addition to the demonstrated role of ceramide and 
cholesterol in EV biogenesis as described above, the polyglycerophospholipid BMP, for 
instance, has been linked to the formation of ILVs by binding of both Alix, an important 
protein of the ESCRT machinery, and the chaperon protein Hsp70 [152, 153]. Furthermore, 
some of the EV-mediated cellular responses have been shown to be lipid-dependent. 
Vesicular displayed prostaglandins can activate intracellular signaling pathways of a target 
cell [154]; other bioactive eicosanoids, including certain leukotrienes, which are associated 
with inflammatory asthma, have been shown to be enriched and functional in EVs [155]; EV-
mediated sphingomyelin has been shown to play a key role in angiogenesis mediated by 
tumor-derived EVs [156], to mention just a few examples of EV lipid-dependent cell-to-cell 
signaling.  
1.6.3 Nucleic Acid Content and Loading 
The presence of nucleic acids in EVs and the effects mediated by nucleic acids, shuttled via 
EVs, constitute a great part of the EV field’s interest, owing to potential new insight into EV 
biology and the idea of utilizing EVs as potential novel therapeutic agents. The presence of 
DNA in EVs has been described by a few groups [157-160]. Whether DNA is truly EV 
bound and not an isolation artefact is however still controversial within the EV research field 
and needs further investigation [122]. The main focus has so far been on different RNA-
species found in EVs (EV-RNA). The predominant forms found in EVs are small RNA, 
below 200 nucleotides (nt) in length, although longer, up to 4.5 kb, have been detected [161-
164]. Various RNA species have been detected in EVs, including mRNAs, miRNAs and 
other long and short non-coding RNA (ncRNA). With the majority of the reads being 
relatively short most of the mRNA and long ncRNA is believed to be fragmented, although 
some appear to be intact. 
The EV-RNA content has been reported to be EV subtype- and cell source-specific [158, 165, 
166] and seems, to a certain degree, to reflect the parental cell source with many common 
transcripts. There is however a disproportional distribution of RNA species in EVs compared 
to the parental cell and it is evident that specific RNA enrichment in EVs occurs [8, 163, 166, 
167]. EVs have for instance been shown to be enriched in retrotransposon sequences, 
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mRNAs encoding transcription factors and proteins involved in alternative splicing, as 
compared to the EV source cell. In contrast, other mRNAs, encoding e.g. mitochondrial or 
cytoskeletal proteins, seem to be relatively low in EVs [158, 163]. Hence, suggesting an EV-
RNA sorting mechanism. In fact, certain specific short mRNA motifs have been suggested to 
be important for mRNA sorting into EVs [168, 169].  
A few different miRNA sorting mechanisms have also been proposed. EV enriched miRNA 
have been demonstrated to often be 3′ uridylated in contrast to 3′ adenylated miRNAs 
generally found in cells [170]. This observation indicates that 3′ end post-transcriptional 
modifications are involved in the sorting of miRNA into EVs. miRNA sorting has also been 
suggested to be associated with a short sorting motif recognized by the RNA binding 
ribonucleoprotein hnRNPA2B1 [171]. Two other hnRNPs were also shown to bind EV-
miRNA, without any identified motifs though, which still however strengthens the concept of 
RNP-mediated loading [171, 172]. Another RNA binding protein, argonaute 2 (AGO2), 
associated with the RISC complex involved in RNA silencing, has been linked to miRNA EV 
sorting. AGO2 sorting has been demonstrated to be dependent on its activation state, as 
phosphorylated AGO2 seemed to inhibit the miRNA-EV sorting, which further indicates a 
controlled sorting mechanism [173-175]. In addition, AGO2 knockout resulted in decreased 
levels of specific EV-miRNA [173]. The presence of AGO2 in EVs is however controversial 
and the AGO2-miRNA complex has been claimed to rather be a co-isolated artefact [123]. A 
fourth suggested miRNA sorting mechanism is the neutral sphingomyelinase 2 (nSMase2)-
dependent pathway. nSMase2 has been linked to EV biogenesis and overexpression of 
nSMase2 has been shown to increase miRNA loading, whereas knock-down of nSMase2 
decreased miRNA EV content [176]. 
1.6.4 Cell Source and Cellular State Dependent Differences of EVs 
EVs, and exosomes in particular, have been shown to share general characteristics, including 
certain proteins, such as tetraspanins, the ESCRT machinery-associated proteins Alix and 
TSG101, and certain heat shock proteins, for instance [143], as well as a general lipid 
composition that is distinct from the cell source. There is however clear evidence of distinct 
cell source-dependent differences between EVs in terms of content and function as 
exemplified above and systematically organized in various EV databases [140-142]. In 
addition, the state of the parental cell also seems to impact the EVs composition and function. 
Cellular maturation state, for instance of dendritic cells (DCs), have shown to have an impact 
on EV composition and function as immature and mature DCs rendered EVs with different 
features [177, 178]. Cells exposed to stress-induced conditions, such as thermal and oxidative 
stress [179-182], acidic conditions [183], serum starvation [184], hypoxia [66, 185], UV-light 
[180], or cell stimulating substances [186-188], generate EVs with a different composition 
and function as compared to EVs isolated from cells under normal conditions. It is however 
questionable how representative or physiologically relevant the common cell flask culturing 
conditions are. In fact, three-dimensional cell culturing in bioreactors or on spheres, which 
reflects the physiological cell conditions better than two-dimensional cultures, seems to give 
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rise to EVs with altered properties compared to corresponding EVs derived from flat plastic 
dishes [189, 190].         
Intense research into protein, lipid and nucleic acid content of EVs is ongoing. With 
continuous developments in isolation methods and characterization techniques and an 
increased awareness of their respective limitations as well as the impact of the cellular state 
and microenvironment, the EV compositions are being unraveled, which will provide further 
insight into the complex functions of EVs.   
 
1.7 INTERCELLULAR COMMUNICATION OF EXTRACELLULAR VESICLES 
The immense interest in the field of EVs during the last decade springs from the recognition 
of EVs as important mediators of cell-to-cell communication. Via transfer of bioactive 
components, EVs take part in physiological conditions and maintenance of homeostasis, but 
also influences various pathological conditions.   
1.7.1 Cellular Uptake of Extracellular Vesicles 
A few different mechanisms have been proposed for how EVs convey their messages and in 
particular how EVs are taken up by the recipient cell. Numerous publications have shown 
uptake of EVs and the evidence of cellular uptake is now indisputable. Experimental designs 
with a variety of different membrane fluorescent dyes, such as PKH26 [191, 192], PKH67 
[129, 130], DiI [193, 194], and DiD [194, 195], as well as fluorescent protein fused to EV-
proteins, such as TSG101-GFP [196] and mCherry-CD63 [136], have shown cellular uptake 
of EVs when observed via e.g. fluorescent microscopy or flow cytometry. The great number 
of observations as well as controlled experiments suggest that there is specific uptake of EVs 
rather than artefacts by free dye or free fluorescent protein. Additional information of EV 
uptake is based on the functional delivery of luminal EV cargo, such as RNA, which must be 
exposed to the recipient cell’s machinery, suggesting a plasma- or intracellular membrane 
fusion, or intracellular disruption of the confining membrane of EVs.   
1.7.2 Membrane Fusion 
Rationally, one of the initial hypotheses was thus that EVs would fuse with the recipient 
cell’s plasma membrane [183, 197]. The merge of EV membrane and plasma membrane has 
been observed via fluorescent lipid dequenching of EVs derived from melanoma as well as 
dendritic cells. The fusion events were increased during acidic conditions, which may 
indicate that this would mostly occur in an acidic tumorigenic microenvironment or 
intracellularly in endosomal departments that are known to have acidic pH conditions [183]. 
Interestingly, a recent publication demonstrated that EVs seem to be rapidly internalized to 
endosomal compartment as single vesicles via cellular filopodia and further shuttled to rough 
ER for cargo display followed by fusion with lysosomal compartments [136].  
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1.7.3 Endocytosis 
The majority of studies do however support an endocytic mechanism as the primary route of 
EV uptake and whether entry via fusion is a rare alternative route or even at all taking place is 
still under debate in the field. Multiple studies have shown that EV uptake is reduced at 4°C, 
indicating that internalization of EVs is an energy-dependent process as opposed to passive 
membrane fusion [130, 146, 194, 198, 199]. Of note, inhibition of the endocytic pathway, by 
depolymerization of actin filament network via Cytochalasin D, has been shown to reduce 
EV internalization, further strengthening the concept of endocytosis-mediated uptake [127, 
129, 130, 197, 200]. Endocytosis includes a variety of different internalization processes and 
EV uptake has been proposed to be mediated by phagocytosis [197, 200], macropinocytosis 
(MP) [129, 199], clathrin-mediated endocytosis (CME) [198, 201] and/or clathrin-
independent endocytosis (CIE) [199, 202]. 
1.7.4 Phagocytosis 
Phagocytosis is a receptor-mediated cellular engulfment of particles. The evidence supporting 
phagocytosis-mediated EV uptake includes observations of inhibited EV internalization of 
macrophages following inhibition of phagocytosis-associated phosphoinositide 3-kinase 
(PI3K), an enzyme that is essential in the formation of phagosomes [200]. In addition, EVs 
labelled with a phagosome tracer, pHrodo that becomes fluorescent at phagosome pH, was 
active in recipient dendritic cells, thus indicating phagocytosis-mediated EV internalization 
[197]. The technical limitations associated with these findings, including specificity of the 
PI3K inhibitors and PI3K, which is also involved in MP, as well as the tracer pHrodo’s 
ability to distinguish phagocytosis compared to other low pH associated endosomal 
pathways, emphasize the need for further validation of the phagocytosis-mediated EV uptake 
theory.  
1.7.5 Clathrin Dependent and Independent Endocytosis 
In contrast to phagocytosis that is associated with specialized phagocytes, CME, CIE and MP 
are endocytosis mechanisms occurring in all cell types. Inhibition of essential components of 
the CME process including inhibition of dynamin2, a GTPase required for CME or treatment 
with chlorpromazine, which prevents clathrin-coated pit formation at the plasma membrane, 
have been shown to decrease EV uptake, thus indicating a role of CME in EV internalization 
[128, 198]. In addition, clathrin-independent endocytosis, such as caveolin-dependent 
endocytosis (CDE), has been described for EV uptake. Of note, dynamin2 is required for both 
CME and CDE. Thus, the findings of decreased EV uptake following dynamin2-inhibition 
cannot be applied to distinguish between these endocytic pathways. In fact, a recent 
publication found that CIE, but not CME, is important for EV internalization [199]. By 
utilizing chemical inhibitors of CIE and siRNA knockdown of caveolin-1, flotillin-1, and 
RhoA, all representing different CIE subclasses, significant reduction of EV uptake was 
observed, whereas knockdown of clathrin heavy chain, representing CME, as well as CME 
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dependent chemical inhibitor, did not affect the EV internalization [199]. The authors further 
demonstrated MP-dependent EV uptake using the same approach.    
1.7.6 Macropinocytosis 
MP resembles phagocytosis, but without the need of direct contact with the internalized 
material, and involves the inward folding of the cell membrane that is then pinched off into 
the intracellular compartment. In addition to the abovementioned study indicating MP-
dependent uptake, alkalization of the receiving cell microenvironment abrogated EV uptake, 
which supports an MP-associated pathway since MP requires acidification of vacuoles [129]. 
Furthermore, the MP pathway might be cell type-specific, since, when using the same 
specific MP-inhibitor, a decreased EV internalization has been observed in HeLa cells and 
microglia, but not in in macrophages [129, 199, 200].  
1.7.7 EV Content and Recipient Cell Dependent Uptake 
EV uptake has been demonstrated to vary depending on recipient cell type. Possible 
mechanisms include cell type-dependent uptake mechanisms, e.g. phagocytes may utilize 
phagocytosis whereas other cells may use MP or CIE as exemplified above. Cell-specific 
attributes important for EV internalization have also been described. For instance, expression 
levels of heparin sulphate proteoglycans, lectin receptors, lipids and protein-protein 
interactions have been shown to govern cell-specific EV uptake [146, 198, 203-205]. 
Differences in uptake have also been reported depending on EV cell source, indicating a 
sensory mechanism in the recipient cell to certain properties displayed by EVs that become 
internalized. A variety of different EV-displayed molecules including tetraspanins, integrins 
and immunoglobulins as well as lipid rafts, sphingolipids, PS and saccharides, have been 
demonstrated to take part in the uptake process [205-209]. 
To summarize, most evidence point toward an endocytosis-mediated cellular internalization 
of EVs, including phagocytosis, macropinocytosis, clathrin-mediated and clathrin-
independent endocytosis, where the specific pathways in play appear to be dependent on the 
receiving cell type. Furthermore, there seems to be an EV cell source-receiving cell type 
relationship dependent uptake mechanism presumably associated with the displayed lipid and 
protein content of the EVs and receiving cells.   
              
1.8 BIODISTRIBUTION OF EXTRACELLULAR VESICLES 
The many findings of the cellular uptake mechanisms have increased our understanding of 
EVs fascinating capacity to modulate recipient cells. The majority of these important studies 
are however based on in vitro findings. To further understand EV trafficking and to evaluate 
EVs as potential therapeutic agents, investigating the fate of EVs in vivo is of uttermost 
importance.  
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1.8.1 General Tissue Distribution of EVs 
Relatively few studies have been specifically conducted to evaluate the biodistribution of 
EVs. These studies do, however, generally indicate a distribution pattern associated with the 
mononuclear phagocyte system (MPS) with accumulation in, among other tissues, liver, 
spleen, and lungs of EVs derived from lymphoma cells [210], melanoma cells [211], breast 
cancer cell lines [212] and prostatic cancer cells (PC3) [212] as well as HEK293T cells [213, 
214]. The MPS is part of the innate immune system with different subsets of APCs patrolling 
the circulation for detection of foreign substances. These findings are coherent with studies of 
other nanoparticles, such as liposomes, which share some EV characteristics, such as 
similarities in size and confinement of a lipid bilayer [215-217]. The impact of MPS on EV 
biodistribution was in fact observed in a recent publication indicating the role of scavenger 
receptor (SR-A)-mediated EV uptake in macrophages. Inhibition of SR-A by dextran 
sulphate dramatically reduced accumulation of EVs in liver [189]. Furthermore, red blood 
cell-derived EVs have been demonstrated to be removed from the circulation by SR-A of 
MPS-associated Kupffer cells [218]. When EVs were injected in a mouse strain with 
impaired innate immune system, a slower uptake in liver and lung was observed compared to 
mice with impaired adaptive immune system and normal mice, further strengthening the role 
of MPS in EV biodistribution [212]. Studies on small nanoparticles (less than 100 nm in 
diameter) have however found less pronounced MPS uptake due to decreased opsonisation 
by pattern recognition receptors of phagocytes, because of the small size and curvature of 
such nanoparticles. Small particles have furthermore been demonstrated to penetrate the 
fenestrations in hepatic and splenic sinusoidal endothelium with subsequent uptake by 
parenchymal cells [219]. Thus, this indicates hepatocyte and splenocyte uptake rather than 
MPS-associated cell uptake. Of note, EVs injected in macrophage depleted mice were found 
to still mainly accumulate in liver and spleen, suggesting non-MPS-associated uptake. The 
clearance of EVs from the circulation was however dramatically decreased in the macrophage 
depleted mice, supporting the importance of macrophages for the uptake of EVs. EVs have 
previously been shown to be cleared from the circulation quite rapidly. Studies with EVs 
derived from melanoma cells [211], splenocytes [186], and erythrocytes [218] reported a 
more than 90% clearance within 30 minutes. However, thrombocyte-derived EVs remained 
in the circulation with a half-life of 5.5 hours [220], indicating differences in clearance 
between different types of EVs. Attempts to increase EV circulation, such as PEGylation, 
which has been demonstrated to increase circulation time of injected EVs, indicate the 
importance of the biophysical properties of EVs in relation to distribution and clearance. 
Furthermore, the isolation of EVs may impact the biodistribution. UC-based isolation, as 
aforementioned, carries a risk of causing EV aggregation and has been shown to result in a 
higher accumulation in pulmonary tissue, most probably due to the lung capillaries being the 
first capillary bed being subject to EV exposure following intravenous injection, compared to 
EVs isolated with ultrafiltration and SEC [87]. A subsequent publication comparing different 
isolation techniques’ impact on clearance did, however, not see any isolation- dependent 
differences [221]. In line with the analytics methods discussed above, isolation technique 
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may, however, have an impact on EV tissue distribution and is a factor that must be 
considered when assessing the uptake of EVs in vivo. 
In summary, it is likely that there are both MPS-associated and non-MPS-associated 
mechanisms governing EV uptake and biodistribution, which might additionally be EV-type 
dependent.       
1.8.2 EV Type-Specific Biodistribution 
The observed impact of EV cell source-dependent properties and the receiving cell type 
differences on EV uptake has led to the subsequent hypothesis that different EVs would have 
a preferential tissue homing capacity, possibly governed by EV type-specific surface 
properties. Surface expression of CD55 and CD59 on EVs has been demonstrated to protect 
from lysis and allow for longer survival in the circulation, offering the ability of EVs to 
distribute in tissues [222]. Clearance of EVs has also been demonstrated to be associated with 
display of PS on EVs [223]. Display of the CD169 ligand (a2,3-linked sialic acid) on certain 
B-cell-derived EVs, have been shown to direct them towards spleen and lymph node 
accumulation by internalization of CD169 positive macrophages residing in these sites. The 
finding that CD169 controls the access of EVs to lymphoid organs was further strengthened 
by the finding that the distribution was altered in the absence of this route in CD169-/- mice 
[224]. Others have demonstrated that EV-displayed saccharides and C-type lectin interaction 
mediate EV uptake in DCs [205]. The homing potential of EVs linked to the display of 
certain integrins was nicely demonstrated by Hoshino, et al. Tumor-derived EVs from 
different malignant cell lines, with known metastatic tissue pattern, were shown to home to 
specific tissues and prepare the pre-metastatic niche. The importance of EV homing was 
further demonstrated by the ability to alter the metastatic tissue pattern of a bone-tropic tumor 
cell towards lung-tropism by injecting EVs derived from a lung-tropic cell line. Proteomic 
analysis, and subsequent knockdown, demonstrated the importance of certain EV-expressed 
integrins in mediating the specific tissue homing properties of these tumor EVs. The 
distribution differences of EVs depending on cell source, as well as dose and injection route 
was further studied in this thesis and is discussed in more detail below in chapter 4.3. In a 
comparison of EVs derived from five different mouse cell lines (melanoma, myoblast, 
fibroblast, endothelial and macrophage-like cells) there were however no significant 
differences in serum clearance, with all EVs having a serum half-life of about four 
minutes.[225] The EVs were engineered to express a fusion protein, Gaussia luciferase 
(gLuc) fused with lactadherin, and the luminescent reporter moiety was also used for 
biodistribution evaluation. Live imaging was conducted 5 minutes after intravenous injection 
and EVs from all cell lines displayed accumulation mainly in liver. The authors concluded 
that the physicochemical and pharmacokinetic properties of EVs from these different cell 
sources are comparable [225]. The sensitivity of assessing the biodistribution based on a two-
dimensional image of the whole mouse at a single time point is however questionable and 
this approach may not enable detection of small, but possibly significant, cell type-dependent 
differences in EV biodistribution. The many findings on EV type-specific surface properties 
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with observed corresponding differences in tissue uptake in vivo, clearly suggests EV-type 
dependent biodistribution. The degree of impact of these alterations in relation to the general 
distribution pattern may however be subtle, but yet important.      
1.8.3  Technical Considerations of EV Biodistribution Studies 
Different techniques of labelling EVs for in vivo tracing have been utilized. Bioluminescent 
fusion proteins have been employed with gLuc that has been shown to have a 1000-fold 
higher intensity compared to the commonly used firefly and renilla luciferases [226]. The 
high sensitivity makes it attractive for tracing small particles in vivo where the signal from a 
relatively small number of luminescent molecules needs to be strong enough to penetrate 
tissues for detection. gLuc has been used in a handful of EV biodistribution publications 
[211, 212, 227, 228]. gLuc is normally a secreted protein, but for EV tracing it has been 
expressed as a fusion protein with lactadherin [211, 227] or the transmembrane domain of 
platelet derived growth factor (PDGF)-receptor [228], for EV incorporation. While the use of 
an EV sorting moiety has advantages with high specificity, i.e. the luminescent protein should 
only be present in EVs with the respective EV sorting domain and thus minimizing the risk of 
signal from non-EV elements, as with lipophilic dyes, this specificity may also be 
disadvantageous, since it will only reflect the EV population carrying the respective EV 
sorting domain. In fact, different biodistribution patterns were reported using different sorting 
constructs. However, the different publications were utilizing EVs from different cell sources 
from different species (HEK293T [228] and B16-BL6 [211]) and at different doses, which is 
possibly the main reasons for the observed differences. The gLuc-lactadherin fusion protein 
was further developed by introducing a biotin acceptor domain that could be utilized for 
conjugation with labelled streptavidin, e.g. with a fluorophore, to offer dual imaging 
possibilities with both bioluminescence and fluorescence of the same EVs [228]. Although an 
elegant approach, it suffers from the same limitations as using gLuc fusions only. 
Other studies have utilized fluorescent lipophilic dyes, such as red and green PKH dyes 
(PKH26 [191, 192] and PKH67 [129, 130], respectively), which have previously been used in 
cell labeling and tracing studies, to label and trace EVs. The most commonly used fluorescent 
lipophilic dye is however, the near-infrared DiR [87, 212, 213, 229], which is highly 
fluorescent when incorporated into membranes and offers high optical tissue penetrance 
owing to near-infrared fluorescence spectrum [230]. Unlike fluorescent or luminescent 
chimeric proteins fused with an EV sorting protein, the lipophilic dyes will most likely 
distribute equally among the EV populations. There are however, other potential limitations 
of using dyes including the risk of having excess or unbound dye as well as reported risks of 
these dyes to contaminate microenvironments, i.e. being transferred to a neighboring 
membrane, which in turn may give rise to artefacts that need to be controlled for [231]. In 
addition, there is a potential risk that the introduced fluorescent/luminescent protein or dye 
will influence the natural biodistribution of EVs, since other displayed properties have been 
shown to alter cellular uptake and tissue distribution.  
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Another approach to trace the EV biodistribution overcomes this latter issue by following 
RNA species believed to be residing in the lumen of EVs. In one study, B-cell-derived EVs 
were loaded with miR-155 mimic by electroporation and injected in miR-155 knock-out mice 
[232]. Perfused and subsequently homogenized tissues were analyzed by real-time PCR, 
displaying a distribution profile with the highest levels of miR-155 in liver, adipose tissue and 
lungs (spleen was not analyzed). In addition, plasma clearance of the EV-associated miR-155 
was in line with previous reports, with a reported 90% clearance within 30 minutes. Prior to 
injections, the EVs were RNase treated in order to reduce the possibility of miR-155 being on 
the outside of EVs and the re-isolated EVs, following RNase treatment, did show a decreased 
amount of miR-155. The authors concluded that free floating miR-155 mimics thus were 
degraded. Although the risk of analyzing free miRNA was addressed, possible limitations 
include incomplete degradation of all the free miRNA, redistributed miRNA during re-
isolation and risk of continuous diffusion out of the EVs of the electroporated miR-155 
mimic. A few publications have utilized the cre/loxP system, described above, to explore 
functional delivery of Cre-mRNA to reporter tissues, including tumors [233] and brain [234], 
with seemingly successful recombination and generation of detectable fluorescence, in vivo. 
These studies indicate the potential of this highly elegant system, which however needs 
further developments if it is to be used for complete biodistribution studies, owing to it being 
quite inefficient even under in vitro settings and not being able to distinguish between 
different cargos, e.g. Cre-mRNA and –protein, to mention a few of the limitations.[233]   
In conclusion, EV biodistribution studies have shown a general distribution pattern associated 
to the MPS with accumulation of EVs often being reported to be highest in liver, spleen and 
lung tissue, although non-MPS dependent tissue distribution and uptake have been 
demonstrated in parallel. Cell source differences and EV type-specific properties seem to 
impact the biodistribution, at least to a certain degree. In addition, as generally in the EV 
research field, there may be an influence on the tissue distribution associated with isolation 
and manipulation of the EVs. 
 
1.9 EVs IN PATHOLOGICAL AND PHYSIOLOGICAL SETTINGS 
When initially discovered, EVs were postulated to take part in sustaining homeostasis and 
function as a mean for cellular disposal of excess proteins, lipids and nucleic acids. The last 
two decades intense research within the EV field, has however revealed that EVs play an 
important role in various other physiological as well as pathological processes. 
1.9.1 EVs and the Immune System 
EVs were first shown to be involved in immune regulation in the breakthrough publication 
from Raposo et. al., where the authors demonstrated that B-lymphocyte-derived EVs 
expressed antigen-presenting MHC II molecules and that these EVs could induce a T-cell 
response [4]. Following this, a number of studies have shown that different APC-derived EVs 
(APC-EVs) carries peptide–MHC I or –MHC II complexes that can directly stimulate CD8+ 
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and CD4+ T cells, respectively [235-237]. However, the potency of APC-EVs to induce a 
cellular response is relatively poor compared to APCs and relatively high concentrations of 
these APC-EVs are required to generate a T-cell response [238, 239]. Hence, indicating that 
this may not be a main pathway of T-cell activation, at least not for the activation of naïve T-
cells, which have been demonstrated to be poorly stimulated by free APC-EVs in vitro [239, 
240]. Nonetheless, EVs have also been shown to generate T-cell response (including naïve T-
cell activation) via APCs, by APC uptake and transfer of EV-associated antigen peptides to 
the MHC molecules of the receiving APCs or by being retained on the APCs’ surface for EV 
presentation of peptide–MHC complexes directly to T cells [240]. For instance, it was 
demonstrated that mycobacterium-infected macrophages generate EVs with mycobacterial 
antigens can promote T-lymphocyte immunity in mice, via DCs [241], thus indicating a role 
of EVs in the communication between infected cells and the immune system. 
Numerous other EV-associated immune regulations have been proposed. EVs derive from 
infected cells can mediate toll-like receptor-dependent inflammatory response [242]; mast 
cell-derived EVs can promote DC maturation [243]; mast cell-dependent B- and T-cell 
activation is, to some extent, mediated by EVs [244]; and MSC [93, 245] and immature DC-
derived EVs [246, 247] have immunosuppressive properties, to mention a few examples of 
findings that illustrate the numerous roles EVs play in the immune system. EVs have 
furthermore been demonstrated to have the ability to convey various cytokines, such as 
interleukin‑1β (IL-1β) [248], IL-6 [249], CXCL8 [250], tumor necrosis factor (TNF) [251], 
and TNF superfamily members including FasL [252], TRAIL [252] and CD40 ligand [244, 
253], that induce a functional immune response, or immune suppression depending on the 
cytokine. It has been suggested that cytokines, when associated to EVs, are more resistant to 
proteases and have an increased biological activity [254]. EVs have been implicated as pro-
inflammatory mediators in a number of pathological conditions, including rheumatoid 
arthritis [255, 256],  atherosclerosis [257], sepsis [258], type 2 diabetes [259, 260] and pre-
eclampsia [261]. In addition, EVs have been shown to play a key role in the important 
suppression of the maternal immune system during pregnancy. Placenta-derived EVs have 
been demonstrated to maintain the immune-privileged site by expression of the pro-apoptotic 
FasL [144], TRAIL [144], and PD-L1 [262], which induce T-lymphocyte killing and 
subsequent T-cell anergy [263]. NK-dependent cytotoxicity has additionally been shown to 
be downregulated by placental-derived EVs, which has been suggested to be mediated by the 
inhibition of NKG2D receptor, by EV presentation of NKG2D ligand [264].    
1.9.2 EVs and Malignancies 
A great number of publications have shown antitumor immunity in response to tumor-derived 
EVs (tEVs) through different mechanisms including natural killer cell and cytotoxic T-
lymphocyte (CTL) response, which can be mediated by T- and B-cell activation by EVs [5, 
81, 265, 266]. For instance, tEVs, carrying tumor antigens, can be efficiently taken up by 
DCs for antigen processing and presentation to tumor-specific CTLs. NK activation of 
Hsp70-containing tEVs is another example of EV-mediated antitumor immunity [266]. In 
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addition, lymph node macrophages have been shown to internalize tEVs and physically 
prevent tEV dissemination [267]. In contrast, malignant tumors also utilize EVs to foster 
tumor-promoting immunity, which resembles the mechanism of placental-derived EVs to 
maintain immune-privilege. Tumor-derived EVs have similarly been demonstrated to 
promote T-lymphocyte apoptosis by expression of FasL [268] and TRAIL [269] and suppress 
NK and CD8+ cytotoxicity [269, 270]. In addition, tEVs presentation of transforming growth 
factor‑β (TGFβ) has been demonstrated to inhibit the maturation of DCs and macrophages in 
vivo and promote regulatory T-cells, either directly or via recruitment of myeloid-derived 
suppressor cells, which inhibit antitumor responses [271, 272]. tEVs have furthermore been 
demonstrated to home to subsequent metastatic sites and induce micro environmental 
changes that prepare the pre-metastatic niche in a number of different malignancies [208, 
273-275]. 
1.9.3 EVs and the Central Nervous System 
Following studies demonstrating the presence of EVs in cerebrospinal fluid (CSF) [78, 79], a 
number of studies have examined the role of EVs in the central nervous system (CNS). It has 
been demonstrated that EVs participate in interneuronal communication [276, 277] and in the 
cross-talk between neurons and glial cells [278], suggesting that EVs participate in 
maintenance of homeostasis and immune regulation of the CNS. Of note, EVs have been 
shown to mediate important processes related to neuroinflammation. Brain-derived EVs have 
been shown to have an altered miRNA profile following traumatic brain injury with increased 
levels of miR-21, which has been suggested to be neuroprotective [279]. EVs have in 
addition been implicated in other neuroinflammatory diseases, such as multiple sclerosis 
[280] and ALS [281], but most evidence of the role of EVs in CNS has been accumulated in 
relation to neurodegenerative diseases. For instance, a-synuclein, which has been implicated 
in Parkinson's disease (PD) and other disorders with Lewy body pathology, has been 
demonstrated to be shuttled by EVs in vitro and in preclinical models, as well as in PD-
patients, where increased levels of a-synuclein in plasma-derived EVs have been detected 
[282]. In addition, several studies have been conducted to investigate the role of EVs in 
Alzheimer’s disease (AD), demonstrating EV-mediated sequestration and spread of the 
pathogenic beta amyloid (Aβ) [283, 284] and phosphorylated Tau [285]. In contrast, EVs 
have also been shown to take part in protective mechanisms related to AD. Neuron-derived 
EVs have been demonstrated to promote clearance of Aβ by microglia and reduce Aβ burden 
in vitro and in vivo [191, 286]. Moreover, MSC-derived EVs have been shown to decrease 
both intracellular and extracellular Aβ levels by presenting enzymatically active neprilysin 
[287]. Thus, EVs seem to play a dual role in AD, with both protective and detrimental 
actions, which plausibly relates to EV type and cell source, and a shift of the balance between 
these two modes of action seems to be associated with disease progression. These findings 
further imply that EVs may represent a potential therapeutic approach for the treatment of 
neuroinflammatory diseases, which will be discussed in more detail in chapter 1.10 and 4.3.    
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Furthermore, several CNS-related infections have been demonstrated to be associated with 
EVs. Prion proteins can be found in EVs and these EVs are infectious [288], which indicates 
the role of EVs in prion diseases. Viral infections that affect CNS, including HIV, HTLV and 
Epstein-Barr virus have been shown to exploit EVs to increase their virulence [289]. HIV 
spread for instance, is aided by EV-mediated transfer of CCR5-receptor to non-immune cells, 
to facilitate the entrance to these cells [290].  
In addition, EVs have been observed to have the capacity to travel from the blood circulation 
to the CNS, indicating their ability to cross the blood brain-barrier (BBB) [9, 167], which 
implies a possible communication route between CNS and peripheral tissues. Of note, 
inflammatory conditions, which are associated with an increased leakiness of BBB, seem to 
facilitate the entry of EVs into CNS [234]. The route of EV entry to the CNS is however still 
unclear and, in addition to BBB-transfer, EVs have been suggested to enter the brain at the 
choroid plexus [291].  
Hence, EVs appear to act as an important messenger and regulator of both physiological and 
pathological processes within CNS as well as to function as a link between CNS and the 
periphery.     
1.9.4 Extracellular Vesicles as Biomarkers 
As discussed above, EVs reflect the cellular state in the body, are involved in pathological 
and physiological processes, and are present in body fluids, such as blood and urine [10]. The 
function of EVs to deliver biochemical information can thus be utilized as a biomedical tool 
to gain information, i.e. as biomarkers. The possibility of taking liquid biopsies and analyze 
EV properties that can be related to pathological conditions has gained a vast interest. There 
are currently several clinical trials investigating the use of EVs as biomarkers, with 
indications including neurological disorders, different types of cancers, liver, lung and kidney 
diseases and diabetes (http://clincaltrials.gov), to mention a few examples. 
In conclusion, EVs have been associated with numerous mechanisms in health and disease, 
which is only partially covered by the discussion above. In fact, there is a vast number of 
publications describing the impact of EVs on many other physiological processes in the 
human body, from embryonic development and tissue repair to vascular biology and liver 
homeostasis, as well as numerous diseases, such as various infections and metabolic 
disorders. The many processes demonstrated to be influenced by EVs, likely with varying 
levels of impact, reflect the importance of EV research and furthermore illustrate the great 
potential of utilizing EVs as biomarkers and the many opportunities to exploit EVs and EV-
mechanisms for therapeutic purposes.     
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1.10 EXTRACELLULAR VESICLES AS THERAPEUTICS 
The multiple observations of the impact of EVs on various processes in the body and their 
ability to transfer bioactive components over biological barriers, as a mean of intercellular 
communication, suggest that EVs could be harnessed for use as therapeutic agents. Potential 
therapeutic approaches include utilizing EVs as drug delivery vectors, immune-modulatory 
and regenerative therapies, and anti-tumor and pathogen vaccines. In fact, the therapeutic 
potential of EVs are now being explored in several clinical trials (CTs), see Table 1 for 
completed and current CTs investigating EV-based therapeutics. 
Table 1 - NIH registered CTs of EV-based therapeutics (http://clinicaltrials.gov).     
NIH, National Institute of Health; CTs, clinical trials; imDC, immature dendritic cells; mDC, mature DCs; GM-
CSF, granulocyte-macrophage colony-stimulating factor; CEA, carcinoembryonic antigen. Adopted from [89]. 
1.10.1 Innate therapeutic potential of EVs  
EV composition and content differs depending on type and state of the cell source, as 
discussed above. The ability of EVs to activate or suppress the immune system, depending on 
the type of EV, can thus be exploited as e.g. vaccines or immune modifiers. Most studies that 
aim to elucidate the therapeutic potential of EVs have utilized EVs originating from MSCs 
Indication Phase, 
patients 
EV source EV manipulation Results (if any) 
Melanoma [6] 
 
Phase I,  
n=15 
imDC, 
autologous 
Pulsed with 
peptides 
Safe, well tolerated. 
2 stable disease, 1 minor 
response (res), 1 partial 
res, 1 mixed res. 
Non-small cell 
lung cancer [7] 
Phase I, 
n=4 
imDC, 
autologous 
Pulsed with 
peptides 
Safe, well tolerated. 4 
stable disease (where 2 
had initial progression).   
Non-small cell 
lung cancer 
[112]  
 
Phase 
II, n=22 
mDC, 
autologous 
Pulsed with 
peptides 
32% with stable disease, 
primary endpoint (>50%) 
not reached. 
Colon cancer 
[111] 
Phase I, 
n=40 
Ascites, 
autologous 
+/- GM-CSF 
induced CEA 
Safe, well tolerated.  
1 stable disease, 1 minor 
res (both in CEA group). 
Colon cancer 
[NCT01294072] 
Phase I, 
n=35 
Plant-
derived 
Loaded with 
curcumin 
- 
Radiation and 
chemotherapy 
induced oral 
mucositis  
[NCT01668849] 
Phase I, 
n=60 
Grape-
derived 
 - 
Type-1 diabetes 
[NCT02138331] 
Phase I, 
n=20 
MSCs, 
allogenic 
unmodified - 
Malignant 
pleural effusion 
[NCT01854866] 
II, 
n=30 
Tumor-
derived 
Loaded with 
chemotherapeutic 
drugs 
- 
Ulcers  
(wound healing) 
[NCT02565264] 
I, 
n=5 
Plasma, 
autologous 
unmodified - 
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and DCs. The rationale for using MSC-derived EVs is based on the knowledge acquired from 
the field of MSC-based cell therapy with numerous preclinical studies indicating regenerative 
and immune modulating properties. Following these findings, MSCs have been used in 
clinical trials for a wide range of indications, including stroke, myocardial diseases, chronic 
obstructive pulmonary disease, liver failure and inflammatory bowel disease, to mention a 
few [134, 292]. The initial hypothesis that MSCs would differentiate to and replace damaged 
tissue was partially abandoned following observations that very few, if any, cells do engraft 
for longer periods in the host [293, 294]. The disease-modulating activity was instead 
suggested to be associated with the secretome of MSCs, which was strengthened by 
observations that MSC conditioned media could convey the beneficial effects of MSCs [295, 
296]. Subsequently, various publications are now demonstrating that MSC-derived EVs 
convey the regenerative and immunomodulatory effects of MSCs in a great number of animal 
models of various indications, such as stroke [297], kidney failure [245, 298], acute lung 
injury [299], myocardial infarction [93, 300, 301], sepsis [302] and liver disease [303, 304]. 
MSC-EVs have furthermore been given to a patient suffering from steroid-resistant GvHD 
under passionate care [95], with observed improvements. The therapeutic effect of MSC-EVs 
has been associated with transfer of different bioactive molecules, such as miR-223 for 
cardioprotection [302], miR-133b for neuroprotection [305], keratinocyte growth factor for 
alveolar protection during lung injury [299], neprilysin for Aβ degradation [287], and anti-
inflammatory TGFβ and human leukocyte antigen-G [95]. A proteomic study of MSC-EVs 
indicates that the therapeutic effect is mediated by a combination of surface receptors, 
signaling molecules, cell adhesion proteins and MSC-associated antigens [306]. 
Immunosuppression properties of umbilical cord-derived MSC-EVs have additionally been 
attributed to their ability to inhibit the migration of inflammatory cells [307]. In contrast, 
pancreas-derived MSC-EVs of diabetic mice have shown immunostimulatory properties, 
which was suggested to be caused by transfer of autoantigens [308, 309].  
Similarly, immature DC-derived EVs have been observed to be immunosuppressive, whereas 
mature DCs EVs are utilized for their immunostimulatory properties [310, 311]. These 
opposing features have been contributed to different expression levels of MHC I and II, and 
co-stimulatory molecules such as CD80, CD86, FasL and PD-L1/2 [312, 313]. These 
observations further indicate the influence of cell source and cellular state on EV-mediated 
effects and the importance of choosing appropriate cell source and culturing conditions when 
applying EVs for therapeutic purposes.      
1.10.2 Extracellular Vesicles as Vaccines 
The initial approach of EV-based therapies utilized the immunostimulatory properties of EVs 
to generate an anti-tumor affect. Following successful preclinical results, two phase I clinical 
trials utilizing autologous DC-derived EVs (Dex) pulsed with tumor antigenic peptides for 
treatment of melanoma and non-small cell lung cancer, respectively, were conducted in 2005 
[6, 7] (Table 1). Both demonstrated feasibility and safety of the EV administration that was 
given weekly over four weeks. The beneficial effects of the therapy were however minor or 
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non-existing. The later demonstrations of either tolerogenic or immunostimulatory effects of 
DC-derived EVs depending on DC maturation, as discussed above, led to a subsequent phase 
II study in France, targeting non-small cell lung cancer [112]. In this CT, the addition of IFN-
γ treatment to the DCs to induce DC maturation and increase immune stimulation was used. 
The anticipated T-cell activation response, observed in preclinical studies, was not seen in the 
patients. However, an increased NK cell activity was observed in some patients. A Chinese 
phase I study, conducted 2008, utilized an alternative antitumor immunotherapy approach by 
isolating EVs from the patients’ ascites fluid (Aex) [111]. Patient suffering from colorectal 
cancer received Aex, with or without adjuvant treatment of granulocyte–macrophage colony-
stimulating factor (GM-CSF), which previously had been found to induce an increased 
antitumor immunity. The treatment seemed safe and was well tolerated, treatment effect was 
however only observed in 2 patients. These clinical trials, as well as numerous preclinical 
studies, indicate that immunostimulatory EV-therapy is a feasible anti-cancer approach and 
that autologous EVs are safe and well-tolerated.  
In addition, EV-based vaccines against pathogens, using pathogen antigen-pulsed or EVs 
derived from infected cells as well as pathogen-derived EVs, have shown promising results 
[242, 314-317]. Similar to eukaryotic cells, parasites, helminths, fungi and bacteria release 
EVs [89]. For instance, bacterial outer membrane vesicles (OMVs) are secreted into the 
extracellular environment and are, similar to eukaryote-derived EVs, enclosed with a lipid 
bilayer and carry bioactive proteins, lipids, nucleic acids and virulence factors. OMVs are 
being assessed as vaccines in clinical trials and are believed to offer an advantage over 
conventional vaccines and be efficient against infectious diseases such as tuberculosis and 
enteric diseases, which currently lack efficient treatments [318].   
Compared to other biological therapeutics, such as cell therapies, EVs cannot divide and 
multiply, suggesting that EVs are safer from a tumorigenic and infectious perspective. 
However, there is a risk of co-isolating pathogens, such as viruses that have similar 
biophysical properties. In addition, EV-mediated transfer of oncogenic molecules to normal 
cells has been demonstrated, when derived from tumor cells [319].   
In summary, preclinical and clinical observations indicate that EV-based vaccines, as anti-
tumor or anti-pathogen treatment, are feasible, well tolerated and render a desired 
immunostimulatory therapeutic effect. However, the risk of contaminating pathogens and 
EV-mediated immune tolerance and potential tumor promoting actions need to be considered 
and controlled for in future clinical trials.  
 
1.10.3 Extracellular Vesicles as Delivery Agents 
Owing to their ability to transfer molecular information between cells and tissues, EVs are 
being explored as natural delivery vectors for different cargos, such as small molecules 
without suitable pharmaceutical properties and RNA-species, which often have been shown 
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to have potent action once in contact with the target, but suffer from issues such as low 
cellular uptake, suboptimal pharmacokinetics, off-target toxicity or stability issues.  
Applying EVs as drug delivery systems (DDS) have for instance been explored for a variety 
of different small molecules, including curcumin, doxorubicin and paclitaxel [320]. 
Preclinical animal studies indicate enhanced potency of the small molecule treatment with 
improved pharmacokinetic profiles including improved brain delivery and tumor penetrance, 
as well as efficient cargo delivery and retention in tumor cells, compared to other vehicles, 
such as liposomes and polymer-based synthetic nanoparticles [320]. Following these 
findings, clinical trials with curcumin or chemotherapeutic drug-loaded EVs are being 
conducted, Table 1. 
It is important to note that loading of cargo into EVs often require manipulation of the EVs or 
the parental cells. The techniques of loading cargo into EVs can be divided into two different 
approaches; exogenous loading, i.e. loading of isolated EVs and endogenous loading, i.e. 
loading during EV biogenesis, see Figure 3. 
 
 
Figure 3 – Illustration of EV loading strategies. 
 
1.10.3.1 Exogenous EV loading 
Various techniques have been explored to load isolated EVs with a therapeutic cargo. 
Incubation of EVs with the anti-inflammatory agent curcumin improved the bioavailability 
and anti-inflammatory effect in a mouse model of inflammation [210]. Similarly, incubating 
EVs and the immunosuppressive miR-150 were shown to generate a miRNA-EV association 
that was functionally active [321]. An interesting improvement in incubation-mediated 
loading was explored in a recent publication using hydrophobically modified siRNA for 
huntingtin mRNA silencing, with demonstrated efficient effect in vitro and in vivo [322]. 
Another approach for EV loading utilizes electroporation to generate transient membrane 
pores to facilitate entrance of RNA species [9] or small molecules [323]. Permeabilization, 
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for loading of cargo into EVs, such as therapeutic proteins, has also been demonstrated by 
saponin, freeze–thaw cycles, sonication, and extrusion [324]. In addition, commercial 
cationic liposomes have been utilized for EV transfection. However, this was found to be 
inapplicable due to the inability to separate EVs and micelles and electroporation was 
suggested to be a superior technique [325]. The different exogenous loading techniques have 
pros and cons, and whether the cargo is loaded into or onto, only associated to EVs, or just 
co-isolated, is often debatable. Furthermore, the loading efficiency seems to be quite varying. 
For instance, electroporation has been suggested to generate as high as 90% loading in some 
publications [325], whereas others have reported very poor loading efficiency [326], which 
has been explained by the formation of siRNA aggregates during electroporation that can be 
misinterpreted as siRNA-loaded EVs. Nevertheless, numerous publications have 
demonstrated successful cargo loading by electroporation and these differences may be due to 
different protocol conditions.  
1.10.3.2 Endogenous EV loading 
In contrast to exogenous loading, endogenous loading implies that cargo is introduced into 
the producer cell to exploit the cellular machinery for cargo sorting into EVs. Similar 
techniques as utilized for direct EV loading, including incubation [327] and transfection [213, 
328, 329] have been used to load small RNA and small molecules endogenously into EVs via 
loading into producer cells. The regulated sorting of RNA into EVs as discussed above, will 
most likely result in varying EV loading efficiency depending on the RNA species. 
Furthermore, there is a risk that the parental cell will be affected by the RNA intended for EV 
sorting, which may subsequently lead to unwanted alterations of the produced EVs.  
1.10.4 Bioengineered Extracellular Vesicles 
In addition to loading EVs with a therapeutic cargo, EVs can be further engineered by 
manipulating the parental cell to produce EVs with a desired trait. The pioneering publication 
by Alvarez-Erviti et. al. utilized EVs for brain targeted delivery of siRNA [9]. To enhance the 
targeting properties of the EVs, a peptide obtained from the rabies viral glycoprotein (RVG) 
was introduced as a targeting peptide on the EV surface by transfecting the parental cells with 
a plasmid encoding Lamp2b, an EV membrane protein, fused to RVG. The parental cell was 
thus engineered to produce EVs with the desired protein, which was sorted onto EVs 
endogenously by the fusion to an EV sorting domain. A subsequent publication demonstrated 
increased tumor targeting and antitumor effects by engineered EVs loaded with doxorubicin 
[323]. The EV source cell was engineered to express Lamp2b fused to αv integrin-specific 
iRGD peptide, which previously had been demonstrated to have efficient tumor targeting 
properties [330]. Another study utilized the transmembrane domain of PDGF-receptor fusion 
to a ligand of epidermal growth factor receptor (EGFR) for the production of engineered EVs 
that displayed increased efficiency of antitumor miRNA delivery to breast cancer cells [213]. 
Similarly, EV display of anti-EGFR nanobodies fused with glycosylphosphatidylinositol 
(GPI)-anchor peptides, for sorting to GPI-rich lipid rafts in EV membranes, was 
demonstrated to generate nanobodies on EVs with increased binding to EGFR-positive tumor 
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cells [331]. Similar engineering approaches have furthermore been utilized to display reporter 
moieties, such as gLuc, on EVs, as aforementioned. Moreover, Sterzenbach et. al. recently 
showed that a protein of interest could be sorted into EVs endogenously by exploiting the 
evolutionarily conserved late-domain (L-domain) pathway [332]. The authors tagged Cre 
recombinase with a WW tag (WW-Cre) that was recognized by the L-domain containing 
protein Ndfip1, which led to sorting into EVs. Functional delivery of WW-Cre by EVs was 
demonstrated by the ability of inducing recombination in floxed reporter cells in vitro and in 
vivo. In addition, engineered hybrid EVs are emerging as an alternative strategy for improved 
delivery. Adeno-associated virus was incorporated into HEK293T-derived EVs to generate 
“vexosomes”, which were demonstrated to improve transduction efficiency and exhibit lower 
immunogenicity as compared to the free viral vector [333]. Similarly, EVs have been fused 
with synthetic liposomes with promising results [334]. A novel strategy of hybrid EVs was 
recently presented by Votteler et. al., where they introduce the concept of enveloped protein 
nanocages (EPNs) [335]. By a variety of synthetic proteins, EPNs, similar to EVs, utilize 
membrane binding, self-assembly, and ESCRT machinery proteins for the biogenesis. The 
EPNs were able to efficiently delivered their content into the cytoplasm of target cells.     
 
In conclusion, EVs are emerging as highly potent therapeutic entities with innate properties 
that can be harnessed as cell free cell-based therapies for immunomodulation. These 
properties can furthermore be combined with loading of bioactive drugs for dual therapeutic 
actions and exploitation of EVs delivery capacities as a natural vector and DDS. In addition, 
bioengineering of EVs offers yet another layer to equip EVs with desired properties, such as 
targeting moieties. 
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2 AIMS 
 
Building on the knowledge acquired in the field, which covers much details of intercellular 
communication and cargo delivery capacities of EVs, the overall objective of this thesis is to 
investigate the therapeutic potential of EVs. In order to further elucidate this, it was important 
to develop an increased understanding of the biodistribution and factors impacting tissue 
accumulation of EVs. In addition, the ability of EVs to deliver functional nucleic acids and 
active proteins in pursuance of improved treatments in disease settings needed further 
investigation. The specific foci of the overall objective and this thesis are stated as the aims of 
the respective paper:  
 
2.1 PAPER I 
• To evaluate the potential of engineered EVs to improve brain targeting by displaying 
the rabies viral glycoprotein (RVG) peptide on EVs (RVG-EVs). 
• Investigate RVG-EVs potential to convey siRNA against alpha-synuclein (a-Syn). 
• Examine siRNA loaded RVG-EVs potential, in a Parkinson’s transgenic disease 
model, to reduce a-Syn and its aggregates in the brains of mice. 
 
2.2 PAPER II 
• To find and evaluate a suitable method for biodistribution studies. 
• Investigate possible homing capacities and variations in tissue distribution of EVs 
from different cell sources. 
• Explore the influence of a targeting moiety, administration routes and possible dose-
dependent variations on the biodistribution of EVs.   
 
2.3 PAPER III 
• To generate and optimize EVs that are engineered to display receptors to sequester 
cytokines and decoy their immunostimulating actions. 
• To evaluate the potential of these decoy EVs to act as anti-inflammatory agents in 
vitro and in vivo in mouse models of systemic inflammation and neuroinflammation. 
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3 METHODOLOGICAL CONSIDERATIONS 
Thorough descriptions of the methods employed in this thesis are presented in the respective 
paper. The presentation below is thus intended as a brief outline and discussion of the most 
important methods.  
3.1 CELL SOURCES  
In paper I, the EVs were isolated from murine DCs that were obtained from bone marrow 
(BM) of the same mouse strain (C57BL/6J) as the mice used in the subsequent in vivo 
experiments, to reduce the potential risk of an immune rejection response. The cells were 
transfected with RVG-Lamp2b or mock plasmid using TransIT LT1 transfection reagent. 24 
hours prior to EV harvest, the medium was changed to EV-depleted culture medium. To 
investigate the potential influence of cell source on EV biodistribution, several different cell 
types were used in paper II. In addition to the DCs described above, EVs were obtained from 
human BM-derived MSCs that had been cultured in serum-free media 48 hours prior to EV 
harvest. The same culturing conditions, 48 hours before EV harvest, was also applied on the 
four different cell lines included in the comparison: Human embryonic kidney (HEK293T) 
cells, rat oligodendrocytes (OLN-93), mouse myoblast (C2C12), and mouse melanoma cells 
(B16-F10). The none-mouse derived cells were included to evaluate possible species-
dependent influence on EV biodistribution in mice. Building on the findings from paper I and 
II, as well as reports from others [134, 336, 337], HEK293T (for in vitro evaluation) and 
immortalized BM-derived MSCs (for in vitro and in vivo evaluation) were utilized in paper 
III.   
3.2 EV ISOLATION 
The isolation procedure was optimized between the studies. The initial steps were however 
similar with harvest of the cell culture conditioned media (CM) before low speed serial 
centrifugation at 300-500 x g followed by a 2,000 x g spin to remove floating cells and cell 
debris. The supernatant was then filtered through a 0.2 µm filter to enrich for smaller EVs. In 
paper I and II, the EVs were then pelleted down by an UC step of about 100,000 x g followed 
by a wash spin at 100,000 x g after re-suspending the pellet, to increase the purity of the EVs. 
The final pellet was then re-suspended to desired volume. Based on reports by our group and 
others [87-89, 106], of the risk of UC-associated contaminations, EV aggregations and 
negative impact on EVs integrity associated with UC, an optimized isolation procedure was 
employed in paper III [106]. The 0.2 µm filtered CM was then run through a hollow fiber 
filter using a TFF system to enrich for and concentrate the EVs. The pre-concentrated CM 
was subsequently loaded onto bind-elute and size exclusion chromatography columns 
(CaptoCore 700) to reduce non-EV-associated proteins. The EV sample was subsequently 
concentrated using a 10 kDa molecular weight cut-off filter to desired volume. 
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3.3 NANOPARTICLE TRACKING ANALYSIS 
As part of characterizing the isolated EVs, NTA was utilized in all papers to measure the size 
and to quantify the EVs in the samples. NTA is based on the movement of nanometer-sized 
particles in a solution, known as Brownian motion. The Strokes-Einstein equation is 
employed to calculate the size of the particles. NanoSight (NS500 nanoparticle analyzer) was 
employed for NTA in all papers. The instrument is equipped with a laser that that gives rise 
to light scattering as the beam passes through the sample and hits the particles. The light 
scatter is visualized and recorded via a CCD camera. In addition, the utilized NS500 is 
equipped with a 488nm laser and a 500nm long pass filter, which can be turned on for 
fluorescent readings or off for light scatter measurements. An NTA software is then used to 
pinpoint the particles and calculate their concentration and size. The instrument can be used 
for particles ranging from 30-1,000 nm in diameter [338, 339]. For all recordings, samples 
were diluted in PBS to achieve a particle count of between 2 x 108 and 2 x 109 per ml, for 
accurate detection of the software. The camera focus was adjusted to make the particles 
appear as sharp dots. The script control function of the software was used to run the sample 
and record the light scattering, and the batch process function was used to analyze the 
sample-recordings.  
3.4 FLOW CYTOMETRY 
The surface expression of EVs was assessed in paper III by bead based multiplex flow 
cytometry analysis. The MACSPlex Exosome KitTM that was utilized has been stated to allow 
for qualitative and semiquantitative analysis of exosomal surface epitopes by flow cytometry 
[120]. This method utilizes fluorescently labelled antibody-coated capture beads that are 
incubated with isolated EVs. The used MACSPlex exosome KitTM includes 39 different 
capture beads targeting human EV surface epitopes (or control epitopes). The pan detection 
reagents with APC-conjugated anti-CD9, anti-CD63 and anti-CD81 antibodies were used to 
detect EVs captured by respective bead subsets. In addition, to detect the expression of the 
decoy receptors IL6ST and TNFR1 on respective EVs, APC-conjugated rat-anti-mouse 
gp130 (IL6ST) antibodies or AlexaFluor647-conjugated mouse-anti-human CD120a 
(TNFR1) antibodies, were used as detection antibodies. Median fluorescence intensities for 
all bead populations were background-corrected by subtracting background/unspecific 
median. All samples were analyzed with a MACSQuant 10 instrument with at least 20,000 
cells or 10,000 beads recorded per sample.  
3.5 TRANSMISSION ELECTRON MICROSCOPY 
TEM was utilized for EV characterization in paper I and III. EVs were added onto glow 
discharged EM grids, which were stained with 2% uranyl acetate to visualize the vesicles. In 
paper III, immuno-EM was performed by incubating the engineered EVs with blocking 
solution, followed by incubation with primary antibodies against respective decoy receptor 
displayed on the EVs. Gold nanoparticles conjugated to protein A or secondary antibody 
were then added and incubated with the mixture, which was then transferred to glow 
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discharged EM grids that were stained and dried before being visualized with a transmission 
electron microscope.   
3.6 DIR LABELLING OF EVS 
In paper I and II, EVs were labelled with the fluorescent lipophilic dye DiR (1,1-dioctadecyl-
3,3,3,3-tetramethylindotricarbocyanineiodide). DiR was chosen due to its near-infrared 
fluorescence spectrum, which offers high optical tissue penetrance. DiR is furthermore 
suitable owing to its properties of low fluorescence when unbound and highly fluorescent 
when incorporated into membranes [230]. The EVs were labelled by incubating the filtered 
CM with 1 µM DiR prior to the UC-based isolation, including a washing step. The DiR 
staining of EVs was evaluated with sucrose gradient to confirm that no free dye was 
remaining after the isolation and that the DiR was associated with the EVs during density 
separation. In addition, unconditioned media was incubated with DiR, ultra-centrifuged with 
a washing step and re-suspended, in the same fashion as the labelled EVs were isolated, to 
serve as a control for injection and tracing of labelled EVs in mice.  
3.7 BIOENGINEERING OF EVs 
In all three papers, chimeric proteins were utilized to display a protein of interest on EVs. The 
fusion constructs were made to encode for an EV sorting domain (such as Lamp2b, CD63 or 
syntenin) and a protein of interest, such as the fluorescent protein eGFP, the brain targeting 
peptide RVG, or the different variants of the cytokine receptors IL-6 signal transducer 
(IL6ST) and the TNF-receptor (TNFR). The respective parental cells were either transiently 
transfected using polyethylenimine (PEI) or TransIT LT1 transfection reagent, or transduced 
with a lentiviral vector encoding the respective construct. To achieve stable expression of the 
vectors, infected cells were selected with puromycin. The engineered EVs were subsequently 
isolated as described above. The presence of the EV-displayed chimeric protein was 
evaluated in all papers by western blot, with the addition of bead based multiplex flow 
cytometry analysis in paper III as described above. The function of the EV-displayed 
chimeric protein was evaluated depending on its intended effect. GFP-displayed EVs were 
analyzed with NanoSight, with and without the long pass filter for fluorescent or light scatter 
measurements, respectively. Functional delivery of siRNA by RVG displayed EVs to 
neuroblastoma cells (SH-SY5Y) were assessed in vitro. The cytokine decoy potential of the 
displayed cytokine receptors was evaluated in reporter cells as described in paper III. Briefly, 
NF-κB reporter (Luc)-HEK293 cells were treated with TNFα and EVs displaying TNFR or 
control EVs, and the luminescence was measured after six hours. Similarly, HEK-Blue IL-6 
cells were treated with either IL-6 or IL-6/IL-6-receptor complex and EVs displaying IL6ST 
or control EVs, and the SEAP levels were quantified after six hours. The in vivo evaluation 
of the surface expressed chimeric proteins is presented below.   
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3.8 IN VIVO TECHNIQUES AND MOUSE DISEASE MODELS 
3.8.1 Parkinson’s Disease Mouse Model 
The potential of utilizing brain targeted EVs as a mean for siRNA-mediated decrease of a-
Syn levels in the brain was examined as a therapeutic approach for Parkinson’s disease. The 
siRNA loaded EVs were assessed in wildtype mice and in a transgenic (Tg) mouse model 
that demonstrates a-Syn expression throughout the brain. Briefly, a-Syn siRNA was 
electroporated into RVG-EVs that had previously been isolated from engineered DCs. The 
RVG-EVs containing siRNAs were pelleted by UC, re-suspended and injected intravenously 
into wildtype or Tg mice. Brains were dissected 3 and 7 days after injection and analyzed for 
a-Syn mRNA and protein levels by quantitative PCR and western blot, respectively. The Tg 
mouse model was established by cloning the human S129D a-Syn cDNA with a C-terminal 
HA tag into the pPrP vector containing the promoter and exons 1 and 2 of the mouse prion 
protein gene. The transgene fragment was isolated from the plasmid vector and microinjected 
into pronuclei of one-cell eggs obtained from C57BL/6 × CBA F1 donors. The presence of a-
Syn in the brain of the Tg mice was evaluated by immunohistochemical detection of S129D 
a-Syn HA expression using an anti-HA antibody. Tissue extracts of different brain regions 
were further assessed by WB, with or without high salt (HS), Triton X-100, and urea to 
indicate the presence of a-Syn aggregates.  In addition, brain sections were stained with the 
green fluorescent dye Thioflavin S (ThioS), which stains amyloid deposits, to further evaluate 
the effect of the injected siRNA loaded RVG-EVs in the Tg mouse model.  
3.8.2 Tissue Distribution of injected EVs 
In order to assess the tissue distribution, EVs from different cell types were isolated and 
labelled with DiR as described above. Mice were intravenously, intraperitoneally, or 
subcutaneously injected with DiR-labelled EVs. The biodistribution of the EVs was analyzed 
by fluorescent measurements of the whole mouse as well as harvested organs, at different 
time points, using the In Vivo Imaging System (IVIS). Perfusion of the blood vessels with 
PBS was conducted to confirm that accumulation of labelled EVs in the different organs. 
Initially, a dose comparison study was conducted with different EV doses, based on NTA 
quantification. The dose of 1.0 x 1010 particles per gram body weight was found to be suitable 
and used in the subsequent experiments. In addition, immunohistochemistry of organs from 
mice injected with CD63-eGFP positive EVs was conducted to analyze the presence of EVs 
without the use of DiR, to validate the experimental set-up.       
3.8.3 LPS Induced Systemic Inflammation 
The engineered EVs used in paper III (termed decoy EVs), display cytokine receptors 
targeting the inflammatory TNFa and IL-6 pathways. To evaluate the anti-inflammatory 
potential of these EVs in vivo, a mouse model of systemic inflammation was used. 
Inflammation in the mice is induced by an intraperitoneal injection of lipopolysaccharide 
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(LPS) [340]. The EVs were subsequently injected via the tail vein and animals were observed 
and weighed daily after induction. 
3.8.4 Experimental Autoimmune Encephalitis 
To evaluate the decoy EVs potential to treat neuroinflammation, a multiple sclerosis mouse 
model, known as experimental autoimmune encephalitis (EAE), was utilized. EAE is induced 
by immunization with an emulsion of MOG35-55 in complete Freund's adjuvant (CFA), 
followed by administration of pertussis toxin. Mice were subcutaneously injected with EVs 
and the disease progression was assessed by daily weight measurements and scored using the 
typical EAE-scoring system, which rates the degree of paralysis [341].  
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4 RESULT AND DISCUSSION 
The papers in this thesis share the general objective of investigating the potential of EVs to be 
employed for therapeutic purposes. The respective paper explores different aspects of this in 
order to, at least partially, increase our understanding of the possibilities of EVs.    
4.1 PAPER I 
Based on previous findings showing that EVs can be loaded with siRNA and be targeted to 
the brain using the brain targeting peptide RVG [9], it was hypothesized that siRNA against 
a-Syn could be delivered via brain targeted EVs to reduce the a-Syn pathological conditions 
associated with Parkinson's disease (PD). First, three different siRNAs against a-Syn were 
evaluated in neuroblastoma SH-SY5Y cells over-expressing mouse a-Syn. The siRNA was 
either introduced to the cells by Hiperfect transfection reagent or via EVs that had been 
engineered to express RVG (Lamp2b-RVG), which had been electroporated with the 
different siRNAs. The results indicated greater reduction in a-Syn mRNA and protein levels 
when the siRNA was delivered via EVs with an 80% mRNA and 85% protein reduction of a-
Syn for the best siRNA candidate. Hence, clearly indicating that targeted EVs efficiently 
deliver functional siRNA to the receiving cells and that the approach is feasible. Following 
this, the brain distribution of intravenously injected RVG-coated EVs were assessed in 
wildtype animals using the fluorescent near infrared DiR, as discussed above, displaying a 
widespread distribution in the brain. Next, wildtype animals were injected with siRNA loaded 
RVG-coated EVs and the brains were analyzed 3 or 7 days post injection, with significant 
decrease of a-Syn mRNA and protein levels.  
To further validate the therapeutic potential of RVG-coated EV delivery of siRNA to treat a-
Syn aggregations, which are believed to be associated with PD, a transgenic (Tg) mouse 
model expressing the phosphomimic human S129D a-Syn was generated. The presence of a-
Syn in the brain of the Tg mice was evaluated by immunohistochemical detection of S129D 
a-Syn HA expression using an anti-HA antibody, displaying a-Syn expression throughout 
the brain. Tissue extracts of different brain regions were further assessed by WB, with or 
without high salt (HS), Triton X-100, and urea to indicate the presence of a-Syn aggregates. 
All analyzed brain regions stained positive for Triton X-100 insoluble a a-Syn. However, it 
was more prominent in the cortex, cerebellum, and striatum, which is in line with previously 
demonstrated increased aggregation associated with S129 phosphorylated a-Syn in Lewy 
bodies in PD [342]. Phenotypic changes in activity and motor skills were not observed. 
However, Triton X-100 insoluble a-Syn was detected in the brain of mice from 3 months and 
increased with age until the endpoint of 24 months, indicating characteristic pathological 
changes associated with PD and the Tg mouse model was thus believed to be suitable for 
further evaluation of the siRNA loaded RVG-EVs.  
Next, siRNA loaded RVG-displayed EVs were assessed in SH-SY5Y cells expressing human 
S129D a-Syn-HA, displaying a dose-response correlated reduction of a-Syn by western blot. 
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Following this, siRNA against a-Syn or control siRNA were loaded into RVG-EVs, which 
were subsequently injected intravenously to 5 months old Tg mice. Again, a significant 
decrease of a-Syn RNA and protein levels was seen in the mice treated with RVG-EVs 
carrying siRNA against a-Syn, whereas no effect was seen with the control siRNA. In 
addition, brain sections were stained with ThioS, which stains amyloid deposits. Tg mice 
treated with RVG-EVs carrying siRNA against a-Syn displayed an 84% decreased staining 
in the midbrain seven days after treatment, as compared to untreated Tg mice, further 
supporting the therapeutic effect of the EV delivered siRNA. Furthermore, 
immunohistochemistry of S129D a-Syn-HA in dopaminergic neurons in the substantia nigra, 
which is pathologically relevant in PD, demonstrated reduced a-Syn-HA puncta in the Tg 
mice treated with RVG-EVs carrying siRNA against a-Syn, compared to control. 
In conclusion, the findings demonstrate that brain targeted EVs can be employed as efficient 
vectors for siRNA therapy against a-Syn pathological conditions, such as PD. 
 
4.2 PAPER II 
In pursuance of using EVs for therapeutic purposes, the fate of the injected EVs must be 
understood. We thus set out to elucidate the biodistribution of exogenous EVs and the 
potential impact of administration route, cell source, dosing and targeting, on the tissue 
distribution of EVs in vivo.  
Following the findings from paper I and based on reports by others [213], the fluorescent 
lipophilic dye DiR was evaluated as an EV labeling tool. The rational was based on the 
properties of DiR, including exhibiting high fluorescence when incorporated into membranes, 
the near-infrared fluorescence spectrum, which offers high optical tissue penetrance, and the 
ability to homogeneously label the EVs [230]. There are however also potential limitations of 
these lipophilic dyes, including the risk of having excess or unbound dye, which may form 
micelles that can be mistaken as EVs. Risk of microenvironment contamination, i.e. the dye 
being transferred to a neighboring cell membrane, has also been reported [231]. Thorough 
assessment of the labelling technique was thus conducted. EVs were labelled and isolated by 
UC, as explained above. The stained EVs or free DiR were then loaded onto a sucrose 
gradient for density based separation. DiR stained EVs were visible and fluoresced at the 
expected density of small EVs. Western blot analysis further confirmed the presence of Alix 
in the same fraction, indicating that DiR thus binds to EVs. As expected, free DiR displayed a 
lower buoyant density and lower fluorescent values, indicating that it was not bound to any 
membrane. To further rule out the risk of monitoring free dye, unconditioned medium 
without EVs was incubated with DiR and subjected to UC in the same fashion as when 
labelling EVs. Following injection of the UC isolated free dye, ex vivo assessment of the 
organs displayed negligible fluorescence, thus indicating that any excess dye would be lost 
during the EV isolation. DiR labelled EVs on the other hand, displayed significant 
fluorescence, with the highest levels originating from liver and spleen. To further confirm 
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that EVs, and not merely the dye, were being traced, CD63-eGFP positive EVs were injected 
in mice. Immunohistochemistry against eGFP on organs harvested 24 hours after injection 
revealed positive staining in the parenchyma of the liver and spleen, which was in line with 
the findings of DiR labelled EVs. Taken together, this thus affirmed that DiR labeling was a 
suitable method for in vivo tracing of EVs. 
EVs were further characterized by NTA, western blot and TEM, which displayed presence of 
EV markers and morphological properties of EVs. Next, a dose comparison study was 
conducted with escalading doses of DiR labelled EVs, which indicated a difference in tissue 
distribution with a relative decrease in the liver uptake with increasing doses. This was 
interpreted as a possible saturation of the MPS. In order to avoid the risk of saturating the 
MPS, the intermediate dose of 1.0 x 1010 particles per gram body weight was used in the 
subsequent experiments.  
Next, a time laps study was undertaken to investigate the kinetics of the EV distribution. The 
overall EV biodistribution profile remained largely unchanged during the first 24 hours, 
although an initial increased pulmonary accumulation was noted at 5 minutes after injection, 
which was then stabilized at relatively lower levels. This might be due to the lung capillaries 
being the first capillary bed being subject to EV exposure following intravenous injection, 
where potentially aggregated EVs are trapped immediately, whereas the slower accumulation 
in the other tissues may reflect the EV uptake from the circulation. In fact, the absolute 
fluorescence levels increased in the organs over time, indicating a continues uptake from the 
circulation. At the later 48-hour time point, greater changes in the relative tissue distribution 
were detected. This may reflect redistribution or a later uptake phase of remaining EVs, or an 
artefact due to the long half-life of the dye. Due to the risk of unspecific signals after 24 
hours, organs were analyzed at 24 hours in the subsequent experiments.    
EVs are commonly injected systemically to assess the effect in vivo. However, different 
routes of injections can be employed for this. To assess whether the route of injection 
influenced the distribution pattern, mice were injected intravenously (i.v), intraperitoneally 
(i.p.) or subcutaneously (s.c). Interestingly, i.p. and s.c. injections showed a significantly 
lower EV accumulation in liver and spleen compared to i.v. injections. In addition, total 
fluorescence was significantly lower in s.c. treated mice, indicating a retention of the EVs 
around the adipose tissue and a possible slow release mechanism. These results show that the 
route of injection influences tissue distribution of EVs and suggest that the injection site 
employed could be adopted to reflect the most preferred biodistribution and/or 
pharmacokinetic profile of a given therapeutic approach.  
To investigate potential intrinsic tropisms of EVs, three different mouse cell sources; a 
muscle cell line (C2C12), a melanoma cell line (B16F10), and primary immature bone 
marrow-derived DCs, two human cell sources (HEK293T and primary human MSCs) and 
rat-derived oligodendrocytes (OLN-93) were utilized as EV sources. The EVs were DiR 
labelled, i.v. injected and the tissue accumulation was evaluated at 24 hours after injection. A 
general distribution pattern, with highest accumulation of EVs in liver, followed by spleen 
 40 
and lungs, was displayed independently of the cell source. However, significant differences 
of the relative EV distribution to liver, spleen and lung were seen between the different cell 
sources. The most significant difference in biodistribution was observed from DC-derived 
EVs that accumulated to a higher extent in the spleen and less in the liver, as compared to the 
other cell sources. This difference might be explained by a natural tropism that could be 
speculated to be governed by cell source dependent repertoire of surface receptors and 
extracellular matrix binding proteins, which is in line with the findings of homing 
mechanisms of EVs related to the display of integrins, as discussed above. This highlights the 
importance of studies on the intercellular communication of EVs, since further investigation 
of EV-tropisms may allow for researchers to hijack these mechanisms and employ them for 
targeted EV therapies. 
Furthermore, based on the reports and clinical trials of utilizing EVs as an antitumor 
treatment, we set out to investigate the distribution of untargeted EVs in tumor-bearing mice. 
Interestingly, 3% of the total tissue fluorescence originated from the tumor of melanoma 
bearing mice. The accumulation of untargeted EVs in the tumor is most probably related to 
the leaky vasculature, which allows entry of EVs. The tumor penetrance can probably be 
further optimized, by e.g tumor targeting moieties. These findings do however support the 
notion that EVs can be utilized as delivery modalities in antitumor therapies.  
Finally, the impact of surface displayed brain targeting moieties on the tissue distribution was 
investigated. Based on the findings in paper I, and by others [9] utilizing RVG for brain 
targeting of EVs, DCs were engineered to generate Lamp2b-RVG positive EVs. 
Interestingly, the general distribution pattern was not affected by the addition of RVG. DC-
derived EVs, with or without RVG, displayed a similar distribution with the greatest 
accumulation in liver and spleen. However, the accumulation in brain was 2-fold higher for 
the targeted EVs. The small, yet significant, changes in the biodistribution of RVG-EVs 
highlights both the sensitivity of the DiR labelling method in detecting subtle differences and 
that RVG as a targeting moiety does not affect the overall tissue distribution of EVs, but still 
increases the accumulation in the targeted organ.  
To conclude, DiR labelling of EV is a suitable method for biodistribution studies and allows 
for in vivo EV tracing with high sensitivity. EVs display a general distribution pattern in vivo 
with high accumulation in liver and spleen. This biodistribution profile of EVs is however, to 
a certain degree, influenced by the administration route, cell source, dosing and targeting. 
 
4.3 PAPER III 
In this project, the bioengineering technology utilized in paper I and II was adapted to 
produce EVs that display therapeutic proteins. A fusion construct, with an EV sorting domain 
and a non-signalling cytokine receptor, was introduced to the parental cell to produce EVs 
that can sequester cytokines, termed decoy EVs. The objective was to exploit the capacity of 
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EVs to convey the immunomodulatory effect of MSCs, to utilize the efficiency of EVs as 
delivery vector and combine this with receptors, devoid of intracellular signalling domains, 
against inflammatory cytokines. Hence, generating an anti-inflammatory therapy that 
combines the beneficial effects of stem cell therapy, EVs as delivery agents and cytokine 
targeted biologics. The central inflammatory pathways of TNFa and IL-6 trans-signalling 
was chosen as targets for the therapy by equipping the EVs with either TNF-receptor 1 
(TNFR1) that binds TNFa and IL-6 signal transducers (IL6ST) that binds the IL-6/IL-6-
receptor (IL6R) complex, both made to be signal-incompetent. First, several fusion protein 
constructs, with different EV sorting domains combined with either TNFR1 or IL6ST were 
created. The constructs were transiently transfected into HEK293T cells and the derived EVs 
were assessed in regard to expression level of respective decoy (TNFR and IL6ST) (by 
western blot, data not shown) and their efficiency to inhibit cytokine dependent reactions in 
reporter cells. For TNFR1 decoy EVs the activity of the downstream transcription factor NF-
κB was measured in HEK293T cells stably expressing NF-κB-luciferase reporter gene, which 
was stimulated by TNFα. For IL6ST decoy EVs the activity of the downstream transcription 
factor STAT3 was monitored using HEK293T cells stably expressing a STAT3-inducible 
secreted alkaline phosphatase (SEAP) reporter gene, stimulated by IL-6 or IL-6/IL-6R 
complex. The results indicated that decoy EVs expressing TNFR1 or IL6ST were most 
efficient when fused to the EV sorting domain syntentin, which is one of the main 
components involved in the biogenesis of exosomes [30]. The potency of the TNFR-1 decoy 
EVs was increased 10-fold by the identification and subsequent removal of a matrix 
metalloprotease (MMP) cleavage site. The decoy EVs were further optimized by introducing 
a multimerization domain; dimerization domain for IL6ST (IL6ST-di) and trimerization 
domain for TNFR1 (TNFR-tr), mimicking the natural state of the respective receptor. In 
order to evaluate the effect of the decoy EVs in vivo they were assessed in an LPS-induced 
systemic inflammation mouse model. Mice injected with HEK293T-derived decoy EVs, 
following LPS challenge, displayed a significantly improved survival with 100% survival up 
to 60 hours compared to 0% survival of mock treated mice. 
In contrast to HEK293T, MSCs constitute a more attractive and clinically relevant cell source 
for therapeutic EVs, as discussed above. Thus, MSCs were transduced with the optimized 
decoy construct for stable production of MSC-derived decoy EVs. Characterization of 
isolated EVs confirmed the surface expression of common EV markers as well as the 
respective decoy proteins by western blot and bead-based flow cytometry, as described 
above. The EVs further demonstrated a characteristic size range of small EVs, with a peak of 
approximately 100 nm as measured by NTA. Immuno-EM further validated the presence of 
EVs and the respective decoy receptor. The functional assessment of the decoy EVs 
demonstrated a dose-dependent inhibition of respective cytokine pathway in the reporter cells 
of NF-κB and STAT3 activity. LPS-induced mice, treated with MSC-derived decoy EVs, 
furthermore displayed a significantly reduced weight loss, which was further improved by 
combinational treatment with both decoy EVs, as compared to unmodified MSC-EVs.  
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Leaning on the findings of EVs ability to overcome biological barriers and penetrate into 
CNS, we hypothesized that decoy EVs could have a therapeutic effect in neuroinflammation. 
To explore this, the mouse model experimental autoimmune encephalitis (EAE), which 
mimics multiple sclerosis in humans, was employed. The fact that EAE is a progressive 
model with symptoms evolving over time and based on the biodistribution studies in paper II, 
indicating a slow release mechanism of EVs injected s.c., this route of administration was 
chosen. Surprisingly, treatment with unmodified MSC EVs did not affect the disease 
progression compared to mock treatment, which is in contrast to previous findings. This 
might be due to non-favourable culturing conditions or that the specific MSCs employed for 
EV production were not optimal for immunomodulation. [134]. In contrast, the MSC-decoy 
EVs (IL6ST-di, TNFR1-tr and combinational treatment) as well as the positive control (anti-
IL6 antibody, Tocilizumab), significantly ameliorates the EAE symptoms at the end point. 
TNFR1-tr and combinational decoy EV treatment furthermore displayed a significantly 
improved bodyweight compared to mock treatment. In addition, the levels of pro-
inflammatory cytokines (TNFα, IL-6 & IL-17a) and chemokines (Cxcl1) in cerebrospinal 
fluid were significantly reduced by combinational decoy EV treatment (TNFR1-tr and 
IL6ST-di) compared to mock treated EAE mice at the end point. 
In conclusion, by utilizing the sorting mechanisms in the biogenesis of exosomes, parental 
cell sources can be engineered to produce EVs that display functional protein therapeutics. 
Here, EVs are engineered to express signal incompetent receptors that sequester the pro-
inflammatory TNFα or IL-6/IL-6R complex. These decoy EVs significantly ameliorate 
systemic inflammation and neuroinflammation in vivo. In addition, this novel platform has 
the potential to be implemented in several disorders where detrimental signal molecules could 
be sequestered. By combining the beneficial effects of stem cell therapies and protein 
therapeutics with a natural delivery vehicle that can overcome biological barriers, engineered 
EVs have great potential to be next generation therapeutics.  
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5 FUTURE PERSPECTIVES 
The intense research within the field of EVs over the last decades has led to an increased 
understanding of EVs’ biogenesis, content and biological function. There are, however, still 
hurdles that need to be managed in many aspects of EV research for optimizing and utilizing 
EVs as therapies, which is illustrated in Figure 4.  
 
 
Figure 4 – Flowchart illustrating the preclinical testing of EVs, adapted from [343]. 
 
Choosing and characterizing an appropriate cell source for EV production, depending on the 
attended therapeutic approach, is of outmost importance. The well-studied MSCs and DCs 
are likely to be utilized, at least in certain disease settings, owing to their immunomodulatory 
properties and previous observations indicating their tolerability and safety. A variety of 
loading procedures and scalable isolation methods are currently being developed and 
optimized. In order to utilize EVs as off-the-shelf drugs, stability and storage must be further 
examined. In addition, the purity and potency of the isolated EVs must be assessed. The 
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therapeutic EVs must further be characterized in relevant pre-clinical models to assess safety 
as well as the pharmacokinetic and pharmacodynamics profile.  
In conclusion, EVs are emerging as highly potent therapeutic entities and this thesis 
highlights the therapeutic potential of the innate properties of EVs and how EVs can be 
utilized for delivery of RNA species and therapeutic proteins in combination with targeting 
moieties. The field is still in its youth, but intense research is currently ongoing to optimize 
isolation and characterization techniques and to dissect the complex EV biology, content and 
function. To me, it thus seems very likely that EVs will become a future platform of highly 
potent multifaceted biopharmaceuticals. 
 
  
  45 
6 CONFLICT OF INTEREST 
 
I am a shareholder of and consultant for Evox Therapeutics Ltd. 
 
 
  
 46 
7 ACKNOWLEDGEMENTS 
This thesis is the culmination of an occasionally trying, sometimes exhausting, often exciting 
and mostly gratifying journey with much laughter and good memories. My doctoral studies 
have been filled with both challenges and joy, which I have tackled and shared with the 
assistance and guidance of a large number of people. I would like to express my gratitude to 
everyone that have supported me throughout the years and made this thesis possible. In 
particular, I would like to acknowledge: 
Firstly, my dear friend and main supervisor Samir EL Andaloussi who introduced me to the 
world of extracellular vesicles. You have always let me explore my ideas and supported me 
when needed, both in research and privately. Thank you for always being generous, always 
pushing for the need to have a balance in life and always wanting to have a break for a chat!  
My co-supervisor, the brilliant professor Edvard Smith, who welcomed me to the lab as an 
unknowing medical student almost 10 years ago. You have always been a great inspiration to 
me! Thank you for believing in me and motivating me when needed! 
My good friend and research sparring partner Joel Nordin. We have had a great journey from 
the first day of medical school and throughout the years in the lab as well as a lot of fun 
outside of work. Thank you for your good heart, always sharing your ideas and your honest 
opinion about mine. I am sure the future will be as much fun! 
Oscar Simonson, who introduced Joel and me to research during our time at medical school. 
Thank you for all your support and all the great memories at and outside of work!  
Per Lundin, the man who sees and grasps opportunities when others see hurdles. Thank you 
for all your hard work, for fun and stimulating discussions, and for introducing me to a new 
abbreviation for each email!   
Helena Sork, when you joined the lab you already had your two beautiful daughters, but now 
you had to put up with three (sometime childish) boys (Samir, Joel, and myself). You 
somehow endured and are now, not only a successful mom, but also an awesome scientist. 
Thank you for always being there and always making me smile!   
Giulia Corso – what happened?! I came back from a few months of clinical rotation, and it 
had turned around; from me giving you some guidance, to you giving me excellent advice. 
You have really blossomed and I am sure you will do great! Thank you for always making 
life a bit brighter when you are around!  
The amazing Dhanu Gupta, the most curious person I have ever met. Your never-ending 
thirst for understanding things and your will to explore your many great ideas (preferably 
with new techniques) will take you far! Thank you for all the fun times and your contagious 
curiosity!  
  47 
Since a year back I have had the pleasure to work closely with André Görgens, one of the 
most sincere and relaxed persons I have ever met. Thank you for always wanting to see the 
positive in people and situations, for all the rewarding discussions we have had and for never 
saying no to have a coffee or a beer!   
I would like to express my gratitude to the Evox crew at KI. Thank you, Ulrika Felldin, for 
always going the extra mile! Thank you, Xiuming Liang, for always having a smile while 
accomplishing brilliant work! Thank you, Manuela Gustafsson, for all your invaluable 
assistance throughout my doctoral period! Thank you, Beklem Bostancioglu, for always 
wanting to improve and discuss new ideas! Thank you, Dara Mohammad, for your 
invaluable input and hard work! Thank you, Anurupa Nagchowdhury, for your great 
support! Thank you, Oskar Gustafsson, for your interesting questions, happy personality and 
hard work! I would also like to send a big thank you to the Evox crew in UK.   
A big thank you to Kariem Ahmed, Fiona Lee and Taavi Lehto, for sharing your 
knowledge and giving invaluable input to research projects, as well as to discussions about 
sport events, music and politics. There is never anything that is too big or too small to 
discuss, and it can be done with both humor and seriousness! 
A special thanks to prof. Matthew Wood and his group, who have always been very 
welcoming and in particular Imre Mäger, with whom I have had the pleasure to have many 
interesting discussions about science and life! 
The man with the extraordinary mind at SU, Mattias Hällbrink. Thank you for all the 
interesting discussions at and outside of the lab, for explaining an extra time when I can’t 
follow and for letting me in on your great ideas and projects. 
The many (past and present) members of MCG that I have had the pleasure to work with; 
Sofia Stenler, Karin Lundin, Anna Berglöf, Eman Zaghloul, Olof Gissberg, Vladimir 
Pabon, Qing Wang, Osama Ahmed and Christina Rocha; as well as Anthony Wright and 
his students Gustav Arvidsson and Amir Mahani. All of you were always there to share 
guidance, rewarding discussions and fun times. 
A special thanks to the administration, Hanna Gador, Emelie Blomberg and Kathrin 
Reisner. You always go the extra mile to help out! I would also like to express my 
appreciation to Moustapha Hassan and the staff in the animal house!   
A huge thanks to all my friends and my family; Mom, you have always been an inspiration 
to me; dad, you will always be my superhero; Victor; you are my twin brother and best 
friend forever; Sofia, you are one of the kindest and the strongest person I know; and Micael, 
you have always been my role model! I want to dedicate the last and greatest thanks to the 
love of my life, my wife Maria. You always challenge me and you always make me want to 
be the best version of me. Thank you! 
 
 48 
8 REFERENCES 
1. Wolf, P., The nature and significance of platelet products in human plasma. Br J 
Haematol, 1967. 13(3): p. 269-88. 
2. Pan, B.T. and R.M. Johnstone, Fate of the transferrin receptor during maturation of 
sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 1983. 
33(3): p. 967-78. 
3. Harding, C. and P. Stahl, Transferrin recycling in reticulocytes: pH and iron are 
important determinants of ligand binding and processing. Biochem Biophys Res 
Commun, 1983. 113(2): p. 650-8. 
4. Raposo, G., et al., B lymphocytes secrete antigen-presenting vesicles. J Exp Med, 
1996. 183(3): p. 1161-72. 
5. Zitvogel, L., et al., Eradication of established murine tumors using a novel cell-free 
vaccine: dendritic cell-derived exosomes. Nat Med, 1998. 4(5): p. 594-600. 
6. Escudier, B., et al., Vaccination of metastatic melanoma patients with autologous 
dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl 
Med, 2005. 3(1): p. 10. 
7. Morse, M.A., et al., A phase I study of dexosome immunotherapy in patients with 
advanced non-small cell lung cancer. J Transl Med, 2005. 3(1): p. 9. 
8. Valadi, H., et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat Cell Biol, 2007. 9(6): p. 654-9. 
9. Alvarez-Erviti, L., et al., Delivery of siRNA to the mouse brain by systemic injection 
of targeted exosomes. Nat Biotechnol, 2011. 29(4): p. 341-5. 
10. S, E.L.A., et al., Extracellular vesicles: biology and emerging therapeutic 
opportunities. Nat Rev Drug Discov, 2013. 12(5): p. 347-57. 
11. Stegmayr, B. and G. Ronquist, Promotive effect on human sperm progressive motility 
by prostasomes. Urol Res, 1982. 10(5): p. 253-7. 
12. Gould, S.J. and G. Raposo, As we wait: coping with an imperfect nomenclature for 
extracellular vesicles. J Extracell Vesicles, 2013. 2. 
13. van der Pol, E., et al., Recent developments in the nomenclature, presence, isolation, 
detection and clinical impact of extracellular vesicles. J Thromb Haemost, 2016. 
14(1): p. 48-56. 
14. Witwer, K.W., et al., Standardization of sample collection, isolation and analysis 
methods in extracellular vesicle research. J Extracell Vesicles, 2013. 2. 
15. Willms, E., et al., Cells release subpopulations of exosomes with distinct molecular 
and biological properties. Sci Rep, 2016. 6: p. 22519. 
16. Lotvall, J., et al., Minimal experimental requirements for definition of extracellular 
vesicles and their functions: a position statement from the International Society for 
Extracellular Vesicles. J Extracell Vesicles, 2014. 3: p. 26913. 
17. Lee, Y., S. El Andaloussi, and M.J. Wood, Exosomes and microvesicles: extracellular 
vesicles for genetic information transfer and gene therapy. Hum Mol Genet, 2012. 
21(R1): p. R125-34. 
  49 
18. Raposo, G. and W. Stoorvogel, Extracellular vesicles: exosomes, microvesicles, and 
friends. J Cell Biol, 2013. 200(4): p. 373-83. 
19. Grant, B.D. and J.G. Donaldson, Pathways and mechanisms of endocytic recycling. 
Nat Rev Mol Cell Biol, 2009. 10(9): p. 597-608. 
20. Akers, J.C., et al., Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, 
retrovirus-like vesicles, and apoptotic bodies. J Neurooncol, 2013. 113(1): p. 1-11. 
21. Abels, E.R. and X.O. Breakefield, Introduction to Extracellular Vesicles: Biogenesis, 
RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol, 2016. 
36(3): p. 301-12. 
22. Denzer, K., et al., Exosome: from internal vesicle of the multivesicular body to 
intercellular signaling device. J Cell Sci, 2000. 113 Pt 19: p. 3365-74. 
23. Thery, C., M. Ostrowski, and E. Segura, Membrane vesicles as conveyors of immune 
responses. Nat Rev Immunol, 2009. 9(8): p. 581-93. 
24. Babst, M., et al., Escrt-III: an endosome-associated heterooligomeric protein complex 
required for mvb sorting. Dev Cell, 2002. 3(2): p. 271-82. 
25. Wollert, T. and J.H. Hurley, Molecular mechanism of multivesicular body biogenesis 
by ESCRT complexes. Nature, 2010. 464(7290): p. 864-9. 
26. Hurley, J.H. and P.I. Hanson, Membrane budding and scission by the ESCRT 
machinery: it's all in the neck. Nat Rev Mol Cell Biol, 2010. 11(8): p. 556-66. 
27. Babst, M., MVB vesicle formation: ESCRT-dependent, ESCRT-independent and 
everything in between. Curr Opin Cell Biol, 2011. 23(4): p. 452-7. 
28. McCullough, J., et al., ALIX-CHMP4 interactions in the human ESCRT pathway. 
Proc Natl Acad Sci U S A, 2008. 105(22): p. 7687-91. 
29. Katoh, K., et al., The ALG-2-interacting protein Alix associates with CHMP4b, a 
human homologue of yeast Snf7 that is involved in multivesicular body sorting. J Biol 
Chem, 2003. 278(40): p. 39104-13. 
30. Baietti, M.F., et al., Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. 
Nat Cell Biol, 2012. 14(7): p. 677-85. 
31. Roucourt, B., et al., Heparanase activates the syndecan-syntenin-ALIX exosome 
pathway. Cell Res, 2015. 25(4): p. 412-28. 
32. Ghossoub, R., et al., Syntenin-ALIX exosome biogenesis and budding into 
multivesicular bodies are controlled by ARF6 and PLD2. Nat Commun, 2014. 5: p. 
3477. 
33. Stuffers, S., et al., Multivesicular endosome biogenesis in the absence of ESCRTs. 
Traffic, 2009. 10(7): p. 925-37. 
34. Trajkovic, K., et al., Ceramide triggers budding of exosome vesicles into 
multivesicular endosomes. Science, 2008. 319(5867): p. 1244-7. 
35. Stenmark, H., Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol, 
2009. 10(8): p. 513-25. 
36. Pereira-Leal, J.B. and M.C. Seabra, Evolution of the Rab family of small GTP-binding 
proteins. J Mol Biol, 2001. 313(4): p. 889-901. 
 50 
37. Zerial, M. and H. McBride, Rab proteins as membrane organizers. Nat Rev Mol Cell 
Biol, 2001. 2(2): p. 107-17. 
38. Schwartz, S.L., et al., Rab GTPases at a glance. J Cell Sci, 2007. 120(Pt 22): p. 3905-
10. 
39. Zhen, Y. and H. Stenmark, Cellular functions of Rab GTPases at a glance. J Cell Sci, 
2015. 128(17): p. 3171-6. 
40. Jordens, I., et al., The Rab7 effector protein RILP controls lysosomal transport by 
inducing the recruitment of dynein-dynactin motors. Curr Biol, 2001. 11(21): p. 1680-
5. 
41. Carroll, K.S., et al., Role of Rab9 GTPase in facilitating receptor recruitment by 
TIP47. Science, 2001. 292(5520): p. 1373-6. 
42. Barbero, P., L. Bittova, and S.R. Pfeffer, Visualization of Rab9-mediated vesicle 
transport from endosomes to the trans-Golgi in living cells. J Cell Biol, 2002. 156(3): 
p. 511-8. 
43. Aivazian, D., R.L. Serrano, and S. Pfeffer, TIP47 is a key effector for Rab9 
localization. J Cell Biol, 2006. 173(6): p. 917-26. 
44. Mobius, W., et al., Immunoelectron microscopic localization of cholesterol using 
biotinylated and non-cytolytic perfringolysin O. J Histochem Cytochem, 2002. 50(1): 
p. 43-55. 
45. Savina, A., et al., Exosome release is regulated by a calcium-dependent mechanism in 
K562 cells. J Biol Chem, 2003. 278(22): p. 20083-90. 
46. Ostrowski, M., et al., Rab27a and Rab27b control different steps of the exosome 
secretion pathway. Nat Cell Biol, 2010. 12(1): p. 19-30; sup pp 1-13. 
47. Hsu, C., et al., Regulation of exosome secretion by Rab35 and its GTPase-activating 
proteins TBC1D10A-C. J Cell Biol, 2010. 189(2): p. 223-32. 
48. Ohya, T., et al., Reconstitution of Rab- and SNARE-dependent membrane fusion by 
synthetic endosomes. Nature, 2009. 459(7250): p. 1091-7. 
49. Tsuboi, T. and M. Fukuda, The C2B domain of rabphilin directly interacts with 
SNAP-25 and regulates the docking step of dense core vesicle exocytosis in PC12 
cells. J Biol Chem, 2005. 280(47): p. 39253-9. 
50. Tsuboi, T. and M. Fukuda, The Slp4-a linker domain controls exocytosis through 
interaction with Munc18-1.syntaxin-1a complex. Mol Biol Cell, 2006. 17(5): p. 2101-
12. 
51. Fukuda, M., Versatile role of Rab27 in membrane trafficking: focus on the Rab27 
effector families. J Biochem, 2005. 137(1): p. 9-16. 
52. Chen, Y.A. and R.H. Scheller, SNARE-mediated membrane fusion. Nat Rev Mol Cell 
Biol, 2001. 2(2): p. 98-106. 
53. Baker, R.W. and F.M. Hughson, Chaperoning SNARE assembly and disassembly. Nat 
Rev Mol Cell Biol, 2016. 17(8): p. 465-79. 
54. Fader, C.M., et al., TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE 
proteins involved in specific steps of the autophagy/multivesicular body pathways. 
Biochim Biophys Acta, 2009. 1793(12): p. 1901-16. 
  51 
55. Bevers, E.M., et al., Lipid translocation across the plasma membrane of mammalian 
cells. Biochim Biophys Acta, 1999. 1439(3): p. 317-30. 
56. Leventis, P.A. and S. Grinstein, The distribution and function of phosphatidylserine in 
cellular membranes. Annu Rev Biophys, 2010. 39: p. 407-27. 
57. Hankins, H.M., et al., Role of flippases, scramblases and transfer proteins in 
phosphatidylserine subcellular distribution. Traffic, 2015. 16(1): p. 35-47. 
58. Hugel, B., et al., Membrane microparticles: two sides of the coin. Physiology 
(Bethesda), 2005. 20: p. 22-7. 
59. Tricarico, C., J. Clancy, and C. D'Souza-Schorey, Biology and biogenesis of shed 
microvesicles. Small GTPases, 2016: p. 1-13. 
60. Yang, J.S., et al., A role for phosphatidic acid in COPI vesicle fission yields insights 
into Golgi maintenance. Nat Cell Biol, 2008. 10(10): p. 1146-53. 
61. Pasquet, J.M., J. Dachary-Prigent, and A.T. Nurden, Calcium influx is a determining 
factor of calpain activation and microparticle formation in platelets. Eur J Biochem, 
1996. 239(3): p. 647-54. 
62. Bucki, R., et al., Calcium induces phospholipid redistribution and microvesicle 
release in human erythrocyte membranes by independent pathways. Biochemistry, 
1998. 37(44): p. 15383-91. 
63. Muralidharan-Chari, V., et al., ARF6-regulated shedding of tumor cell-derived 
plasma membrane microvesicles. Curr Biol, 2009. 19(22): p. 1875-85. 
64. Nabhan, J.F., et al., Formation and release of arrestin domain-containing protein 1-
mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 
protein. Proc Natl Acad Sci U S A, 2012. 109(11): p. 4146-51. 
65. Tauro, B.J., et al., Comparison of ultracentrifugation, density gradient separation, 
and immunoaffinity capture methods for isolating human colon cancer cell line 
LIM1863-derived exosomes. Methods, 2012. 56(2): p. 293-304. 
66. Wang, T., et al., Hypoxia-inducible factors and RAB22A mediate formation of 
microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad 
Sci U S A, 2014. 111(31): p. E3234-42. 
67. Johnstone, R.M., et al., Vesicle formation during reticulocyte maturation. Association 
of plasma membrane activities with released vesicles (exosomes). J Biol Chem, 1987. 
262(19): p. 9412-20. 
68. Thery, C., et al., Molecular characterization of dendritic cell-derived exosomes. 
Selective accumulation of the heat shock protein hsc73. J Cell Biol, 1999. 147(3): p. 
599-610. 
69. Hawari, F.I., et al., Release of full-length 55-kDa TNF receptor 1 in exosome-like 
vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad 
Sci U S A, 2004. 101(5): p. 1297-302. 
70. Graner, M.W., et al., Proteomic and immunologic analyses of brain tumor exosomes. 
FASEB J, 2009. 23(5): p. 1541-57. 
71. Caby, M.P., et al., Exosomal-like vesicles are present in human blood plasma. Int 
Immunol, 2005. 17(7): p. 879-87. 
 52 
72. Muller, L., et al., Isolation of biologically-active exosomes from human plasma. J 
Immunol Methods, 2014. 411: p. 55-65. 
73. Pisitkun, T., R.F. Shen, and M.A. Knepper, Identification and proteomic profiling of 
exosomes in human urine. Proc Natl Acad Sci U S A, 2004. 101(36): p. 13368-73. 
74. Dimov, I., L. Jankovic Velickovic, and V. Stefanovic, Urinary exosomes. 
ScientificWorldJournal, 2009. 9: p. 1107-18. 
75. Ronquist, G. and I. Brody, The prostasome: its secretion and function in man. 
Biochim Biophys Acta, 1985. 822(2): p. 203-18. 
76. Park, K.H., et al., Ca2+ signaling tools acquired from prostasomes are required for 
progesterone-induced sperm motility. Sci Signal, 2011. 4(173): p. ra31. 
77. Admyre, C., et al., Exosomes with immune modulatory features are present in human 
breast milk. J Immunol, 2007. 179(3): p. 1969-78. 
78. Vella, L.J., et al., Packaging of prions into exosomes is associated with a novel 
pathway of PrP processing. J Pathol, 2007. 211(5): p. 582-90. 
79. Harrington, M.G., et al., The morphology and biochemistry of nanostructures provide 
evidence for synthesis and signaling functions in human cerebrospinal fluid. 
Cerebrospinal Fluid Res, 2009. 6: p. 10. 
80. Asea, A., et al., Heat shock protein-containing exosomes in mid-trimester amniotic 
fluids. J Reprod Immunol, 2008. 79(1): p. 12-7. 
81. Andre, F., et al., Malignant effusions and immunogenic tumour-derived exosomes. 
Lancet, 2002. 360(9329): p. 295-305. 
82. Runz, S., et al., Malignant ascites-derived exosomes of ovarian carcinoma patients 
contain CD24 and EpCAM. Gynecol Oncol, 2007. 107(3): p. 563-71. 
83. Masyuk, A.I., et al., Biliary exosomes influence cholangiocyte regulatory mechanisms 
and proliferation through interaction with primary cilia. Am J Physiol Gastrointest 
Liver Physiol, 2010. 299(4): p. G990-9. 
84. Ogawa, Y., et al., Proteomic analysis of two types of exosomes in human whole 
saliva. Biol Pharm Bull, 2011. 34(1): p. 13-23. 
85. Thery, C., et al., Isolation and characterization of exosomes from cell culture 
supernatants and biological fluids. Curr Protoc Cell Biol, 2006. Chapter 3: p. Unit 3 
22. 
86. Momen-Heravi, F., et al., Current methods for the isolation of extracellular vesicles. 
Biol Chem, 2013. 394(10): p. 1253-62. 
87. Nordin, J.Z., et al., Ultrafiltration with size-exclusion liquid chromatography for high 
yield isolation of extracellular vesicles preserving intact biophysical and functional 
properties. Nanomedicine, 2015. 11(4): p. 879-83. 
88. Linares, R., et al., High-speed centrifugation induces aggregation of extracellular 
vesicles. J Extracell Vesicles, 2015. 4: p. 29509. 
89. Lener, T., et al., Applying extracellular vesicles based therapeutics in clinical trials - 
an ISEV position paper. J Extracell Vesicles, 2015. 4: p. 30087. 
90. Lamparski, H.G., et al., Production and characterization of clinical grade exosomes 
derived from dendritic cells. J Immunol Methods, 2002. 270(2): p. 211-26. 
  53 
91. Cantin, R., et al., Discrimination between exosomes and HIV-1: purification of both 
vesicles from cell-free supernatants. J Immunol Methods, 2008. 338(1-2): p. 21-30. 
92. Boing, A.N., et al., Single-step isolation of extracellular vesicles by size-exclusion 
chromatography. J Extracell Vesicles, 2014. 3. 
93. Arslan, F., et al., Mesenchymal stem cell-derived exosomes increase ATP levels, 
decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial 
viability and prevent adverse remodeling after myocardial ischemia/reperfusion 
injury. Stem Cell Res, 2013. 10(3): p. 301-12. 
94. Alvarez, M.L., et al., Comparison of protein, microRNA, and mRNA yields using 
different methods of urinary exosome isolation for the discovery of kidney disease 
biomarkers. Kidney Int, 2012. 82(9): p. 1024-32. 
95. Kordelas, L., et al., MSC-derived exosomes: a novel tool to treat therapy-refractory 
graft-versus-host disease. Leukemia, 2014. 28(4): p. 970-3. 
96. Clayton, A., et al., Analysis of antigen presenting cell derived exosomes, based on 
immuno-magnetic isolation and flow cytometry. J Immunol Methods, 2001. 247(1-2): 
p. 163-74. 
97. Koga, K., et al., Purification, characterization and biological significance of tumor-
derived exosomes. Anticancer Res, 2005. 25(6A): p. 3703-7. 
98. Chen, C., et al., Microfluidic isolation and transcriptome analysis of serum 
microvesicles. Lab Chip, 2010. 10(4): p. 505-11. 
99. Davies, R.T., et al., Microfluidic filtration system to isolate extracellular vesicles from 
blood. Lab Chip, 2012. 12(24): p. 5202-10. 
100. Cvjetkovic, A., J. Lotvall, and C. Lasser, The influence of rotor type and 
centrifugation time on the yield and purity of extracellular vesicles. J Extracell 
Vesicles, 2014. 3. 
101. Momen-Heravi, F., et al., Impact of biofluid viscosity on size and sedimentation 
efficiency of the isolated microvesicles. Front Physiol, 2012. 3: p. 162. 
102. Webber, J. and A. Clayton, How pure are your vesicles? J Extracell Vesicles, 2013. 2. 
103. Yuana, Y., et al., Co-isolation of extracellular vesicles and high-density lipoproteins 
using density gradient ultracentrifugation. J Extracell Vesicles, 2014. 3. 
104. Cheruvanky, A., et al., Rapid isolation of urinary exosomal biomarkers using a 
nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol, 2007. 
292(5): p. F1657-61. 
105. Heinemann, M.L., et al., Benchtop isolation and characterization of functional 
exosomes by sequential filtration. J Chromatogr A, 2014. 1371: p. 125-35. 
106. Corso, G., et al., Reproducible and scalable purification of extracellular vesicles 
using combined bind-elute and size exclusion chromatography. Sci Rep, 2017. 7(1): 
p. 11561. 
107. Van Deun, J., et al., The impact of disparate isolation methods for extracellular 
vesicles on downstream RNA profiling. J Extracell Vesicles, 2014. 3. 
108. Logozzi, M., et al., High levels of exosomes expressing CD63 and caveolin-1 in 
plasma of melanoma patients. PLoS One, 2009. 4(4): p. e5219. 
 54 
109. Nakai, W., et al., A novel affinity-based method for the isolation of highly purified 
extracellular vesicles. Sci Rep, 2016. 6: p. 33935. 
110. Liga, A., et al., Exosome isolation: a microfluidic road-map. Lab Chip, 2015. 15(11): 
p. 2388-94. 
111. Dai, S., et al., Phase I clinical trial of autologous ascites-derived exosomes combined 
with GM-CSF for colorectal cancer. Mol Ther, 2008. 16(4): p. 782-90. 
112. Besse, B., et al., Dendritic cell-derived exosomes as maintenance immunotherapy 
after first line chemotherapy in NSCLC. Oncoimmunology, 2016. 5(4): p. e1071008. 
113. Heijnen, H.F., et al., Activated platelets release two types of membrane vesicles: 
microvesicles by surface shedding and exosomes derived from exocytosis of 
multivesicular bodies and alpha-granules. Blood, 1999. 94(11): p. 3791-9. 
114. Yuana, Y., et al., Atomic force microscopy: a novel approach to the detection of 
nanosized blood microparticles. J Thromb Haemost, 2010. 8(2): p. 315-23. 
115. Maas, S.L., et al., Possibilities and limitations of current technologies for 
quantification of biological extracellular vesicles and synthetic mimics. J Control 
Release, 2015. 200: p. 87-96. 
116. Thery, C., L. Zitvogel, and S. Amigorena, Exosomes: composition, biogenesis and 
function. Nat Rev Immunol, 2002. 2(8): p. 569-79. 
117. Ettelaie, C., et al., Characterization of physical properties of tissue factor-containing 
microvesicles and a comparison of ultracentrifuge-based recovery procedures. J 
Extracell Vesicles, 2014. 3. 
118. Keller, S., et al., Body fluid derived exosomes as a novel template for clinical 
diagnostics. J Transl Med, 2011. 9: p. 86. 
119. Poliakov, A., et al., Structural heterogeneity and protein composition of exosome-like 
vesicles (prostasomes) in human semen. Prostate, 2009. 69(2): p. 159-67. 
120. Koliha, N., et al., A novel multiplex bead-based platform highlights the diversity of 
extracellular vesicles. J Extracell Vesicles, 2016. 5: p. 29975. 
121. Kowal, J., et al., Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S 
A, 2016. 113(8): p. E968-77. 
122. Mateescu, B., et al., Obstacles and opportunities in the functional analysis of 
extracellular vesicle RNA - an ISEV position paper. J Extracell Vesicles, 2017. 6(1): 
p. 1286095. 
123. Arroyo, J.D., et al., Argonaute2 complexes carry a population of circulating 
microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A, 
2011. 108(12): p. 5003-8. 
124. Wei, Z., et al., Fetal Bovine Serum RNA Interferes with the Cell Culture derived 
Extracellular RNA. Sci Rep, 2016. 6: p. 31175. 
125. Chevillet, J.R., et al., Quantitative and stoichiometric analysis of the microRNA 
content of exosomes. Proc Natl Acad Sci U S A, 2014. 111(41): p. 14888-93. 
  55 
126. Kreimer, S., et al., Mass-spectrometry-based molecular characterization of 
extracellular vesicles: lipidomics and proteomics. J Proteome Res, 2015. 14(6): p. 
2367-84. 
127. Atay, S., C. Gercel-Taylor, and D.D. Taylor, Human trophoblast-derived exosomal 
fibronectin induces pro-inflammatory IL-1beta production by macrophages. Am J 
Reprod Immunol, 2011. 66(4): p. 259-69. 
128. Barres, C., et al., Galectin-5 is bound onto the surface of rat reticulocyte exosomes 
and modulates vesicle uptake by macrophages. Blood, 2010. 115(3): p. 696-705. 
129. Fitzner, D., et al., Selective transfer of exosomes from oligodendrocytes to microglia 
by macropinocytosis. J Cell Sci, 2011. 124(Pt 3): p. 447-58. 
130. Morelli, A.E., et al., Endocytosis, intracellular sorting, and processing of exosomes 
by dendritic cells. Blood, 2004. 104(10): p. 3257-66. 
131. Zomer, A., et al., In Vivo imaging reveals extracellular vesicle-mediated 
phenocopying of metastatic behavior. Cell, 2015. 161(5): p. 1046-1057. 
132. Zomer, A., et al., Studying extracellular vesicle transfer by a Cre-loxP method. Nat 
Protoc, 2016. 11(1): p. 87-101. 
133. Tkach, M., et al., Qualitative differences in T-cell activation by dendritic cell-derived 
extracellular vesicle subtypes. EMBO J, 2017. 
134. Heldring, N., et al., Therapeutic Potential of Multipotent Mesenchymal Stromal Cells 
and Their Extracellular Vesicles. Hum Gene Ther, 2015. 26(8): p. 506-17. 
135. Larson, M.C., et al., Calcium-phosphate microprecipitates mimic microparticles 
when examined with flow cytometry. Cytometry A, 2013. 83(2): p. 242-50. 
136. Heusermann, W., et al., Exosomes surf on filopodia to enter cells at endocytic hot 
spots, traffic within endosomes, and are targeted to the ER. J Cell Biol, 2016. 213(2): 
p. 173-84. 
137. Steen, H.B., Flow cytometer for measurement of the light scattering of viral and other 
submicroscopic particles. Cytometry A, 2004. 57(2): p. 94-9. 
138. Nolte-'t Hoen, E.N., et al., Quantitative and qualitative flow cytometric analysis of 
nanosized cell-derived membrane vesicles. Nanomedicine, 2012. 8(5): p. 712-20. 
139. Welsh, J.A., et al., Extracellular Vesicle Flow Cytometry Analysis and 
Standardization. Front Cell Dev Biol, 2017. 5: p. 78. 
140. Mathivanan, S. and R.J. Simpson, ExoCarta: A compendium of exosomal proteins 
and RNA. Proteomics, 2009. 9(21): p. 4997-5000. 
141. Kalra, H., et al., Vesiclepedia: a compendium for extracellular vesicles with 
continuous community annotation. PLoS Biol, 2012. 10(12): p. e1001450. 
142. Kim, D.K., et al., EVpedia: an integrated database of high-throughput data for 
systemic analyses of extracellular vesicles. J Extracell Vesicles, 2013. 2. 
143. Thery, C., et al., Proteomic analysis of dendritic cell-derived exosomes: a secreted 
subcellular compartment distinct from apoptotic vesicles. J Immunol, 2001. 166(12): 
p. 7309-18. 
144. Stenqvist, A.C., et al., Exosomes secreted by human placenta carry functional Fas 
ligand and TRAIL molecules and convey apoptosis in activated immune cells, 
 56 
suggesting exosome-mediated immune privilege of the fetus. J Immunol, 2013. 
191(11): p. 5515-23. 
145. Shimoda, M. and R. Khokha, Proteolytic factors in exosomes. Proteomics, 2013. 
13(10-11): p. 1624-36. 
146. Christianson, H.C., et al., Cancer cell exosomes depend on cell-surface heparan 
sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad 
Sci U S A, 2013. 110(43): p. 17380-5. 
147. Sinha, A., et al., In-depth proteomic analyses of ovarian cancer cell line exosomes 
reveals differential enrichment of functional categories compared to the NCI 60 
proteome. Biochem Biophys Res Commun, 2014. 445(4): p. 694-701. 
148. Zaborowski, M.P., et al., Extracellular Vesicles: Composition, Biological Relevance, 
and Methods of Study. Bioscience, 2015. 65(8): p. 783-797. 
149. Biro, E., et al., The phospholipid composition and cholesterol content of platelet-
derived microparticles: a comparison with platelet membrane fractions. J Thromb 
Haemost, 2005. 3(12): p. 2754-63. 
150. Simons, K. and J.L. Sampaio, Membrane organization and lipid rafts. Cold Spring 
Harb Perspect Biol, 2011. 3(10): p. a004697. 
151. Record, M., et al., Exosomes as new vesicular lipid transporters involved in cell-cell 
communication and various pathophysiologies. Biochim Biophys Acta, 2014. 
1841(1): p. 108-20. 
152. Matsuo, H., et al., Role of LBPA and Alix in multivesicular liposome formation and 
endosome organization. Science, 2004. 303(5657): p. 531-4. 
153. Kirkegaard, T., et al., Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-
associated lysosomal pathology. Nature, 2010. 463(7280): p. 549-53. 
154. Subra, C., et al., Exosomes account for vesicle-mediated transcellular transport of 
activatable phospholipases and prostaglandins. J Lipid Res, 2010. 51(8): p. 2105-20. 
155. Esser, J., et al., Exosomes from human macrophages and dendritic cells contain 
enzymes for leukotriene biosynthesis and promote granulocyte migration. J Allergy 
Clin Immunol, 2010. 126(5): p. 1032-40, 1040 e1-4. 
156. Kim, C.W., et al., Extracellular membrane vesicles from tumor cells promote 
angiogenesis via sphingomyelin. Cancer Res, 2002. 62(21): p. 6312-7. 
157. Guescini, M., et al., Astrocytes and Glioblastoma cells release exosomes carrying 
mtDNA. J Neural Transm (Vienna), 2010. 117(1): p. 1-4. 
158. Balaj, L., et al., Tumour microvesicles contain retrotransposon elements and 
amplified oncogene sequences. Nat Commun, 2011. 2: p. 180. 
159. Waldenstrom, A., et al., Cardiomyocyte microvesicles contain DNA/RNA and convey 
biological messages to target cells. PLoS One, 2012. 7(4): p. e34653. 
160. Kahlert, C., et al., Identification of double-stranded genomic DNA spanning all 
chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients 
with pancreatic cancer. J Biol Chem, 2014. 289(7): p. 3869-75. 
  57 
161. Batagov, A.O. and I.V. Kurochkin, Exosomes secreted by human cells transport 
largely mRNA fragments that are enriched in the 3'-untranslated regions. Biol Direct, 
2013. 8: p. 12. 
162. Huang, X., et al., Characterization of human plasma-derived exosomal RNAs by deep 
sequencing. BMC Genomics, 2013. 14: p. 319. 
163. Eirin, A., et al., MicroRNA and mRNA cargo of extracellular vesicles from porcine 
adipose tissue-derived mesenchymal stem cells. Gene, 2014. 551(1): p. 55-64. 
164. Tang, Y.T., et al., Comparison of isolation methods of exosomes and exosomal RNA 
from cell culture medium and serum. Int J Mol Med, 2017. 40(3): p. 834-844. 
165. Crescitelli, R., et al., Distinct RNA profiles in subpopulations of extracellular vesicles: 
apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles, 2013. 2. 
166. Ferguson, S.W. and J. Nguyen, Exosomes as therapeutics: The implications of 
molecular composition and exosomal heterogeneity. J Control Release, 2016. 228: p. 
179-190. 
167. Skog, J., et al., Glioblastoma microvesicles transport RNA and proteins that promote 
tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 
1470-6. 
168. Bolukbasi, M.F., et al., miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in 
Microvesicles. Mol Ther Nucleic Acids, 2012. 1: p. e10. 
169. Batagov, A.O., V.A. Kuznetsov, and I.V. Kurochkin, Identification of nucleotide 
patterns enriched in secreted RNAs as putative cis-acting elements targeting them to 
exosome nano-vesicles. BMC Genomics, 2011. 12 Suppl 3: p. S18. 
170. Koppers-Lalic, D., et al., Nontemplated nucleotide additions distinguish the small 
RNA composition in cells from exosomes. Cell Rep, 2014. 8(6): p. 1649-1658. 
171. Villarroya-Beltri, C., et al., Sumoylated hnRNPA2B1 controls the sorting of miRNAs 
into exosomes through binding to specific motifs. Nat Commun, 2013. 4: p. 2980. 
172. Villarroya-Beltri, C., et al., Sorting it out: regulation of exosome loading. Semin 
Cancer Biol, 2014. 28: p. 3-13. 
173. Guduric-Fuchs, J., et al., Selective extracellular vesicle-mediated export of an 
overlapping set of microRNAs from multiple cell types. BMC Genomics, 2012. 13: p. 
357. 
174. McKenzie, A.J., et al., KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes. 
Cell Rep, 2016. 15(5): p. 978-987. 
175. Melo, S.A., et al., Cancer exosomes perform cell-independent microRNA biogenesis 
and promote tumorigenesis. Cancer Cell, 2014. 26(5): p. 707-21. 
176. Kosaka, N., et al., Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal 
transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem, 
2013. 288(15): p. 10849-59. 
177. Segura, E., S. Amigorena, and C. Thery, Mature dendritic cells secrete exosomes with 
strong ability to induce antigen-specific effector immune responses. Blood Cells Mol 
Dis, 2005. 35(2): p. 89-93. 
 58 
178. Yin, W., et al., Immature dendritic cell-derived exosomes: a promise subcellular 
vaccine for autoimmunity. Inflammation, 2013. 36(1): p. 232-40. 
179. Clayton, A., et al., Induction of heat shock proteins in B-cell exosomes. J Cell Sci, 
2005. 118(Pt 16): p. 3631-8. 
180. Eldh, M., et al., Exosomes communicate protective messages during oxidative stress; 
possible role of exosomal shuttle RNA. PLoS One, 2010. 5(12): p. e15353. 
181. Hedlund, M., et al., Thermal- and oxidative stress causes enhanced release of 
NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and 
B cells. PLoS One, 2011. 6(2): p. e16899. 
182. Atienzar-Aroca, S., et al., Oxidative stress in retinal pigment epithelium cells 
increases exosome secretion and promotes angiogenesis in endothelial cells. J Cell 
Mol Med, 2016. 20(8): p. 1457-66. 
183. Parolini, I., et al., Microenvironmental pH is a key factor for exosome traffic in tumor 
cells. J Biol Chem, 2009. 284(49): p. 34211-22. 
184. Li, J., et al., Serum-free culture alters the quantity and protein composition of 
neuroblastoma-derived extracellular vesicles. J Extracell Vesicles, 2015. 4: p. 26883. 
185. Kucharzewska, P., et al., Exosomes reflect the hypoxic status of glioma cells and 
mediate hypoxia-dependent activation of vascular cells during tumor development. 
Proc Natl Acad Sci U S A, 2013. 110(18): p. 7312-7. 
186. Saunderson, S.C., et al., Induction of exosome release in primary B cells stimulated 
via CD40 and the IL-4 receptor. J Immunol, 2008. 180(12): p. 8146-52. 
187. Pusic, A.D., et al., IFNgamma-stimulated dendritic cell exosomes as a potential 
therapeutic for remyelination. J Neuroimmunol, 2014. 266(1-2): p. 12-23. 
188. Groth, E., et al., Stimulated release and functional activity of surface expressed 
metalloproteinase ADAM17 in exosomes. Biochim Biophys Acta, 2016. 1863(11): p. 
2795-2808. 
189. Watson, D.C., et al., Efficient production and enhanced tumor delivery of engineered 
extracellular vesicles. Biomaterials, 2016. 105: p. 195-205. 
190. Madrigal, M., K.S. Rao, and N.H. Riordan, A review of therapeutic effects of 
mesenchymal stem cell secretions and induction of secretory modification by different 
culture methods. J Transl Med, 2014. 12: p. 260. 
191. Yuyama, K., et al., Sphingolipid-modulated exosome secretion promotes clearance of 
amyloid-beta by microglia. J Biol Chem, 2012. 287(14): p. 10977-89. 
192. Franzen, C.A., et al., Characterization of uptake and internalization of exosomes by 
bladder cancer cells. Biomed Res Int, 2014. 2014: p. 619829. 
193. Obregon, C., et al., Exovesicles from human activated dendritic cells fuse with resting 
dendritic cells, allowing them to present alloantigens. Am J Pathol, 2006. 169(6): p. 
2127-36. 
194. Tian, T., et al., Dynamics of exosome internalization and trafficking. J Cell Physiol, 
2013. 228(7): p. 1487-95. 
195. Tian, T., et al., Visualizing of the cellular uptake and intracellular trafficking of 
exosomes by live-cell microscopy. J Cell Biochem, 2010. 111(2): p. 488-96. 
  59 
196. Villarroya-Beltri, C., et al., ISGylation controls exosome secretion by promoting 
lysosomal degradation of MVB proteins. Nat Commun, 2016. 7: p. 13588. 
197. Montecalvo, A., et al., Mechanism of transfer of functional microRNAs between 
mouse dendritic cells via exosomes. Blood, 2012. 119(3): p. 756-66. 
198. Escrevente, C., et al., Interaction and uptake of exosomes by ovarian cancer cells. 
BMC Cancer, 2011. 11: p. 108. 
199. Costa Verdera, H., et al., Cellular uptake of extracellular vesicles is mediated by 
clathrin-independent endocytosis and macropinocytosis. J Control Release, 2017. 
266: p. 100-108. 
200. Feng, D., et al., Cellular internalization of exosomes occurs through phagocytosis. 
Traffic, 2010. 11(5): p. 675-87. 
201. Tian, T., et al., Exosome uptake through clathrin-mediated endocytosis and 
macropinocytosis and mediating miR-21 delivery. J Biol Chem, 2014. 289(32): p. 
22258-67. 
202. Nanbo, A., et al., Exosomes derived from Epstein-Barr virus-infected cells are 
internalized via caveola-dependent endocytosis and promote phenotypic modulation 
in target cells. J Virol, 2013. 87(18): p. 10334-47. 
203. Naslund, T.I., et al., Exosomes from breast milk inhibit HIV-1 infection of dendritic 
cells and subsequent viral transfer to CD4+ T cells. AIDS, 2014. 28(2): p. 171-80. 
204. Xie, Y., et al., Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to 
inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I 
and Fas ligand-mediated cytotoxicity. J Immunol, 2010. 185(9): p. 5268-78. 
205. Hao, S., et al., Mature dendritic cells pulsed with exosomes stimulate efficient 
cytotoxic T-lymphocyte responses and antitumour immunity. Immunology, 2007. 
120(1): p. 90-102. 
206. Johnstone, R.M., Exosomes biological significance: A concise review. Blood Cells 
Mol Dis, 2006. 36(2): p. 315-21. 
207. Mulcahy, L.A., R.C. Pink, and D.R. Carter, Routes and mechanisms of extracellular 
vesicle uptake. J Extracell Vesicles, 2014. 3. 
208. Hoshino, A., et al., Tumour exosome integrins determine organotropic metastasis. 
Nature, 2015. 527(7578): p. 329-35. 
209. Wei, X., et al., Surface Phosphatidylserine Is Responsible for the Internalization on 
Microvesicles Derived from Hypoxia-Induced Human Bone Marrow Mesenchymal 
Stem Cells into Human Endothelial Cells. PLoS One, 2016. 11(1): p. e0147360. 
210. Sun, D., et al., A novel nanoparticle drug delivery system: the anti-inflammatory 
activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther, 2010. 
18(9): p. 1606-14. 
211. Takahashi, Y., et al., Visualization and in vivo tracking of the exosomes of murine 
melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol, 2013. 
165(2): p. 77-84. 
212. Smyth, T., et al., Biodistribution and delivery efficiency of unmodified tumor-derived 
exosomes. J Control Release, 2015. 199: p. 145-55. 
 60 
213. Ohno, S.-i., et al., Systemically Injected Exosomes Targeted to EGFR Deliver 
Antitumor MicroRNA to Breast Cancer Cells. Molecular Therapy, 2013. 21(1): p. 
185-191. 
214. Lai, C.P., B.A. Tannous, and X.O. Breakefield, Noninvasive in vivo monitoring of 
extracellular vesicles. Methods Mol Biol, 2014. 1098: p. 249-58. 
215. Ostro, M.J. and P.R. Cullis, Use of liposomes as injectable-drug delivery systems. Am 
J Hosp Pharm, 1989. 46(8): p. 1576-87. 
216. Lopez-Berestein, G., et al., Clinical pharmacology of 99mTc-labeled liposomes in 
patients with cancer. Cancer Res, 1984. 44(1): p. 375-8. 
217. Liu, D., A. Mori, and L. Huang, Role of liposome size and RES blockade in 
controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim 
Biophys Acta, 1992. 1104(1): p. 95-101. 
218. Willekens, F.L., et al., Liver Kupffer cells rapidly remove red blood cell-derived 
vesicles from the circulation by scavenger receptors. Blood, 2005. 105(5): p. 2141-5. 
219. Sarin, H., Physiologic upper limits of pore size of different blood capillary types and 
another perspective on the dual pore theory of microvascular permeability. J 
Angiogenes Res, 2010. 2: p. 14. 
220. Rank, A., et al., Clearance of platelet microparticles in vivo. Platelets, 2011. 22(2): p. 
111-6. 
221. Yamashita, T., et al., Effect of exosome isolation methods on physicochemical 
properties of exosomes and clearance of exosomes from the blood circulation. Eur J 
Pharm Biopharm, 2016. 98: p. 1-8. 
222. Clayton, A., et al., Antigen-presenting cell exosomes are protected from complement-
mediated lysis by expression of CD55 and CD59. Eur J Immunol, 2003. 33(2): p. 522-
31. 
223. Dasgupta, S.K., et al., Lactadherin and clearance of platelet-derived microvesicles. 
Blood, 2009. 113(6): p. 1332-9. 
224. Saunderson, S.C., et al., CD169 mediates the capture of exosomes in spleen and 
lymph node. Blood, 2014. 123(2): p. 208-16. 
225. Charoenviriyakul, C., et al., Cell type-specific and common characteristics of 
exosomes derived from mouse cell lines: Yield, physicochemical properties, and 
pharmacokinetics. Eur J Pharm Sci, 2017. 96: p. 316-322. 
226. Tannous, B.A., Gaussia luciferase reporter assay for monitoring biological processes 
in culture and in vivo. Nat Protoc, 2009. 4(4): p. 582-91. 
227. Imai, T., et al., Macrophage-dependent clearance of systemically administered 
B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles, 
2015. 4: p. 26238. 
228. Lai, C.P., et al., Dynamic biodistribution of extracellular vesicles in vivo using a 
multimodal imaging reporter. ACS Nano, 2014. 8(1): p. 483-494. 
229. Hu, L., et al., Exosomes derived from human adipose mensenchymal stem cells 
accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. 
Sci Rep, 2016. 6: p. 32993.
  61 
230. Texier, I., et al., Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence 
imaging. J Biomed Opt, 2009. 14(5): p. 054005. 
231. Lassailly, F., E. Griessinger, and D. Bonnet, "Microenvironmental contaminations" 
induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell 
tracking. Blood, 2010. 115(26): p. 5347-54. 
232. Bala, S., et al., Biodistribution and function of extracellular miRNA-155 in mice. Sci 
Rep, 2015. 5: p. 10721. 
233. Zomer, A., et al., In Vivo imaging reveals extracellular vesicle-mediated 
phenocopying of metastatic behavior. Cell, 2015. 161(5): p. 1046-57. 
234. Ridder, K., et al., Extracellular vesicle-mediated transfer of genetic information 
between the hematopoietic system and the brain in response to inflammation. PLoS 
Biol, 2014. 12(6): p. e1001874. 
235. Muntasell, A., A.C. Berger, and P.A. Roche, T cell-induced secretion of MHC class 
II-peptide complexes on B cell exosomes. EMBO J, 2007. 26(19): p. 4263-72. 
236. Admyre, C., et al., Exosomes with major histocompatibility complex class II and co-
stimulatory molecules are present in human BAL fluid. Eur Respir J, 2003. 22(4): p. 
578-83. 
237. Andre, F., et al., Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-
derived exosomes transfer functional MHC class I/peptide complexes to dendritic 
cells. J Immunol, 2004. 172(4): p. 2126-36. 
238. Nolte-'t Hoen, E.N., et al., Activated T cells recruit exosomes secreted by dendritic 
cells via LFA-1. Blood, 2009. 113(9): p. 1977-81. 
239. Admyre, C., et al., Direct exosome stimulation of peripheral human T cells detected 
by ELISPOT. Eur J Immunol, 2006. 36(7): p. 1772-81. 
240. Thery, C., et al., Indirect activation of naive CD4+ T cells by dendritic cell-derived 
exosomes. Nat Immunol, 2002. 3(12): p. 1156-62. 
241. Giri, P.K. and J.S. Schorey, Exosomes derived from M. Bovis BCG infected 
macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. 
PLoS One, 2008. 3(6): p. e2461. 
242. Bhatnagar, S., et al., Exosomes released from macrophages infected with intracellular 
pathogens stimulate a proinflammatory response in vitro and in vivo. Blood, 2007. 
110(9): p. 3234-44. 
243. Skokos, D., et al., Mast cell-derived exosomes induce phenotypic and functional 
maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol, 
2003. 170(6): p. 3037-45. 
244. Skokos, D., et al., Mast cell-dependent B and T lymphocyte activation is mediated by 
the secretion of immunologically active exosomes. J Immunol, 2001. 166(2): p. 868-
76. 
245. Bruno, S., et al., Microvesicles derived from mesenchymal stem cells enhance survival 
in a lethal model of acute kidney injury. PLoS One, 2012. 7(3): p. e33115. 
246. Peche, H., et al., Presentation of donor major histocompatibility complex antigens by 
bone marrow dendritic cell-derived exosomes modulates allograft rejection. 
Transplantation, 2003. 76(10): p. 1503-10. 
 62 
247. Kim, S.H., et al., Exosomes derived from IL-10-treated dendritic cells can suppress 
inflammation and collagen-induced arthritis. J Immunol, 2005. 174(10): p. 6440-8. 
248. MacKenzie, A., et al., Rapid secretion of interleukin-1beta by microvesicle shedding. 
Immunity, 2001. 15(5): p. 825-35. 
249. Kandere-Grzybowska, K., et al., IL-1 induces vesicular secretion of IL-6 without 
degranulation from human mast cells. J Immunol, 2003. 171(9): p. 4830-6. 
250. Baj-Krzyworzeka, M., et al., Tumour-derived microvesicles contain interleukin-8 and 
modulate production of chemokines by human monocytes. Anticancer Res, 2011. 
31(4): p. 1329-35. 
251. Zhang, H.G., et al., A membrane form of TNF-alpha presented by exosomes delays T 
cell activation-induced cell death. J Immunol, 2006. 176(12): p. 7385-93. 
252. Munich, S., et al., Dendritic cell exosomes directly kill tumor cells and activate 
natural killer cells via TNF superfamily ligands. Oncoimmunology, 2012. 1(7): p. 
1074-1083. 
253. Sprague, D.L., et al., Platelet-mediated modulation of adaptive immunity: unique 
delivery of CD154 signal by platelet-derived membrane vesicles. Blood, 2008. 
111(10): p. 5028-36. 
254. Zuccato, E., et al., Sorting of Fas ligand to secretory lysosomes is regulated by mono-
ubiquitylation and phosphorylation. J Cell Sci, 2007. 120(Pt 1): p. 191-9. 
255. Boilard, E., et al., Platelets amplify inflammation in arthritis via collagen-dependent 
microparticle production. Science, 2010. 327(5965): p. 580-3. 
256. Cloutier, N., et al., The exposure of autoantigens by microparticles underlies the 
formation of potent inflammatory components: the microparticle-associated immune 
complexes. EMBO Mol Med, 2013. 5(2): p. 235-49. 
257. Hoyer, F.F., et al., Monocytic microparticles promote atherogenesis by modulating 
inflammatory cells in mice. J Cell Mol Med, 2012. 16(11): p. 2777-88. 
258. Prakash, P.S., et al., Human microparticles generated during sepsis in patients with 
critical illness are neutrophil-derived and modulate the immune response. J Trauma 
Acute Care Surg, 2012. 73(2): p. 401-6; discussion 406-7. 
259. Aswad, H., et al., Exosomes participate in the alteration of muscle homeostasis 
during lipid-induced insulin resistance in mice. Diabetologia, 2014. 57(10): p. 2155-
64. 
260. Ying, W., et al., Adipose Tissue Macrophage-Derived Exosomal miRNAs Can 
Modulate In Vivo and In Vitro Insulin Sensitivity. Cell, 2017. 171(2): p. 372-384 e12. 
261. Holder, B.S., et al., Heightened pro-inflammatory effect of preeclamptic placental 
microvesicles on peripheral blood immune cells in humans. Biol Reprod, 2012. 86(4): 
p. 103. 
262. Kshirsagar, S.K., et al., Immunomodulatory molecules are released from the first 
trimester and term placenta via exosomes. Placenta, 2012. 33(12): p. 982-90. 
263. Sabapatha, A., C. Gercel-Taylor, and D.D. Taylor, Specific isolation of placenta-
derived exosomes from the circulation of pregnant women and their 
immunoregulatory consequences. Am J Reprod Immunol, 2006. 56(5-6): p. 345-55. 
  63 
264. Hedlund, M., et al., Human placenta expresses and secretes NKG2D ligands via 
exosomes that down-modulate the cognate receptor expression: evidence for 
immunosuppressive function. J Immunol, 2009. 183(1): p. 340-51. 
265. Wolfers, J., et al., Tumor-derived exosomes are a source of shared tumor rejection 
antigens for CTL cross-priming. Nat Med, 2001. 7(3): p. 297-303. 
266. Elsner, L., et al., The heat shock protein HSP70 promotes mouse NK cell activity 
against tumors that express inducible NKG2D ligands. J Immunol, 2007. 179(8): p. 
5523-33. 
267. Pucci, F., et al., SCS macrophages suppress melanoma by restricting tumor-derived 
vesicle-B cell interactions. Science, 2016. 352(6282): p. 242-6. 
268. Andreola, G., et al., Induction of lymphocyte apoptosis by tumor cell secretion of 
FasL-bearing microvesicles. J Exp Med, 2002. 195(10): p. 1303-16. 
269. Huber, V., et al., Human colorectal cancer cells induce T-cell death through release 
of proapoptotic microvesicles: role in immune escape. Gastroenterology, 2005. 
128(7): p. 1796-804. 
270. Taylor, D.D., et al., T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by 
Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer 
Res, 2003. 9(14): p. 5113-9. 
271. Valenti, R., et al., Human tumor-released microvesicles promote the differentiation of 
myeloid cells with transforming growth factor-beta-mediated suppressive activity on 
T lymphocytes. Cancer Res, 2006. 66(18): p. 9290-8. 
272. Yu, S., et al., Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J 
Immunol, 2007. 178(11): p. 6867-75. 
273. Hood, J.L., R.S. San, and S.A. Wickline, Exosomes released by melanoma cells 
prepare sentinel lymph nodes for tumor metastasis. Cancer Res, 2011. 71(11): p. 
3792-801. 
274. Grange, C., et al., Microvesicles released from human renal cancer stem cells 
stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res, 2011. 
71(15): p. 5346-56. 
275. Peinado, H., et al., Melanoma exosomes educate bone marrow progenitor cells 
toward a pro-metastatic phenotype through MET. Nat Med, 2012. 18(6): p. 883-91. 
276. Chivet, M., et al., Exosomes as a novel way of interneuronal communication. 
Biochem Soc Trans, 2013. 41(1): p. 241-4. 
277. Lachenal, G., et al., Release of exosomes from differentiated neurons and its 
regulation by synaptic glutamatergic activity. Mol Cell Neurosci, 2011. 46(2): p. 409-
18. 
278. Antonucci, F., et al., Microvesicles released from microglia stimulate synaptic activity 
via enhanced sphingolipid metabolism. EMBO J, 2012. 31(5): p. 1231-40. 
279. Harrison, E.B., et al., Traumatic brain injury increases levels of miR-21 in 
extracellular vesicles: implications for neuroinflammation. FEBS Open Bio, 2016. 
6(8): p. 835-46. 
280. Saenz-Cuesta, M., I. Osorio-Querejeta, and D. Otaegui, Extracellular Vesicles in 
Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci, 2014. 8: p. 100. 
 64 
281. Zondler, L., et al., Impaired activation of ALS monocytes by exosomes. Immunol Cell 
Biol, 2017. 95(2): p. 207-214. 
282. Loov, C., et al., alpha-Synuclein in Extracellular Vesicles: Functional Implications 
and Diagnostic Opportunities. Cell Mol Neurobiol, 2016. 36(3): p. 437-48. 
283. Rajendran, L., et al., Alzheimer's disease beta-amyloid peptides are released in 
association with exosomes. Proc Natl Acad Sci U S A, 2006. 103(30): p. 11172-7. 
284. Joshi, P., et al., Microglia convert aggregated amyloid-beta into neurotoxic forms 
through the shedding of microvesicles. Cell Death Differ, 2014. 21(4): p. 582-93. 
285. Saman, S., et al., Exosome-associated tau is secreted in tauopathy models and is 
selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol 
Chem, 2012. 287(6): p. 3842-9. 
286. Yuyama, K., et al., Decreased amyloid-beta pathologies by intracerebral loading of 
glycosphingolipid-enriched exosomes in Alzheimer model mice. J Biol Chem, 2014. 
289(35): p. 24488-98. 
287. Katsuda, T., et al., Human adipose tissue-derived mesenchymal stem cells secrete 
functional neprilysin-bound exosomes. Sci Rep, 2013. 3: p. 1197. 
288. Porto-Carreiro, I., et al., Prions and exosomes: from PrPc trafficking to PrPsc 
propagation. Blood Cells Mol Dis, 2005. 35(2): p. 143-8. 
289. Sampey, G.C., et al., Exosomes and their role in CNS viral infections. J Neurovirol, 
2014. 20(3): p. 199-208. 
290. Mack, M., et al., Transfer of the chemokine receptor CCR5 between cells by 
membrane-derived microparticles: a mechanism for cellular human 
immunodeficiency virus 1 infection. Nat Med, 2000. 6(7): p. 769-75. 
291. Grapp, M., et al., Choroid plexus transcytosis and exosome shuttling deliver folate 
into brain parenchyma. Nat Commun, 2013. 4: p. 2123. 
292. Squillaro, T., G. Peluso, and U. Galderisi, Clinical Trials With Mesenchymal Stem 
Cells: An Update. Cell Transplant, 2016. 25(5): p. 829-48. 
293. Humphreys, B.D., et al., Intrinsic epithelial cells repair the kidney after injury. Cell 
Stem Cell, 2008. 2(3): p. 284-91. 
294. Pittenger, M., Sleuthing the source of regeneration by MSCs. Cell Stem Cell, 2009. 
5(1): p. 8-10. 
295. Timmers, L., et al., Reduction of myocardial infarct size by human mesenchymal stem 
cell conditioned medium. Stem Cell Res, 2007. 1(2): p. 129-37. 
296. van Koppen, A., et al., Human embryonic mesenchymal stem cell-derived conditioned 
medium rescues kidney function in rats with established chronic kidney disease. PLoS 
One, 2012. 7(6): p. e38746. 
297. Xin, H., et al., Systemic administration of exosomes released from mesenchymal 
stromal cells promote functional recovery and neurovascular plasticity after stroke in 
rats. J Cereb Blood Flow Metab, 2013. 33(11): p. 1711-5. 
298. Reis, L.A., et al., Bone marrow-derived mesenchymal stem cells repaired but did not 
prevent gentamicin-induced acute kidney injury through paracrine effects in rats. 
PLoS One, 2012. 7(9): p. e44092. 
  65 
299. Zhu, Y.G., et al., Human mesenchymal stem cell microvesicles for treatment of 
Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells, 2014. 
32(1): p. 116-25. 
300. Lai, R.C., et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion 
injury. Stem Cell Res, 2010. 4(3): p. 214-22. 
301. Bian, S., et al., Extracellular vesicles derived from human bone marrow mesenchymal 
stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med 
(Berl), 2014. 92(4): p. 387-97. 
302. Wang, X., et al., Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited 
Cardioprotection in Polymicrobial Sepsis. Sci Rep, 2015. 5: p. 13721. 
303. Tan, C.Y., et al., Mesenchymal stem cell-derived exosomes promote hepatic 
regeneration in drug-induced liver injury models. Stem Cell Res Ther, 2014. 5(3): p. 
76. 
304. Li, T., et al., Exosomes derived from human umbilical cord mesenchymal stem cells 
alleviate liver fibrosis. Stem Cells Dev, 2013. 22(6): p. 845-54. 
305. Xin, H., et al., Exosome-mediated transfer of miR-133b from multipotent 
mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem 
Cells, 2012. 30(7): p. 1556-64. 
306. Kim, H.S., et al., Proteomic analysis of microvesicles derived from human 
mesenchymal stem cells. J Proteome Res, 2012. 11(2): p. 839-49. 
307. Bai, L., et al., Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental 
Autoimmune Uveitis. Sci Rep, 2017. 7(1): p. 4323. 
308. Sheng, H., et al., Insulinoma-released exosomes or microparticles are 
immunostimulatory and can activate autoreactive T cells spontaneously developed in 
nonobese diabetic mice. J Immunol, 2011. 187(4): p. 1591-600. 
309. Rahman, M.J., et al., Exosomes released by islet-derived mesenchymal stem cells 
trigger autoimmune responses in NOD mice. Diabetes, 2014. 63(3): p. 1008-20. 
310. Robbins, P.D. and A.E. Morelli, Regulation of immune responses by extracellular 
vesicles. Nat Rev Immunol, 2014. 14(3): p. 195-208. 
311. Tian, H. and W. Li, Dendritic cell-derived exosomes for cancer immunotherapy: hope 
and challenges. Ann Transl Med, 2017. 5(10): p. 221. 
312. Kim, S.H., et al., Exosomes derived from genetically modified DC expressing FasL 
are anti-inflammatory and immunosuppressive. Mol Ther, 2006. 13(2): p. 289-300. 
313. Thomson, A.W. and P.D. Robbins, Tolerogenic dendritic cells for autoimmune 
disease and transplantation. Ann Rheum Dis, 2008. 67 Suppl 3: p. iii90-6. 
314. Haneberg, B., et al., Intranasal administration of a meningococcal outer membrane 
vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with 
strong bactericidal activity in humans. Infect Immun, 1998. 66(4): p. 1334-41. 
315. Aline, F., et al., Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes 
induce a protective immune response against T. gondii infection. Infect Immun, 2004. 
72(7): p. 4127-37. 
 66 
316. Roy, K., et al., Outer membrane vesicles induce immune responses to virulence 
proteins and protect against colonization by enterotoxigenic Escherichia coli. Clin 
Vaccine Immunol, 2011. 18(11): p. 1803-8. 
317. Singh, P.P., et al., Exosomes isolated from mycobacteria-infected mice or cultured 
macrophages can recruit and activate immune cells in vitro and in vivo. J Immunol, 
2012. 189(2): p. 777-85. 
318. Kaparakis-Liaskos, M. and R.L. Ferrero, Immune modulation by bacterial outer 
membrane vesicles. Nat Rev Immunol, 2015. 15(6): p. 375-87. 
319. Al-Nedawi, K., et al., Intercellular transfer of the oncogenic receptor EGFRvIII by 
microvesicles derived from tumour cells. Nat Cell Biol, 2008. 10(5): p. 619-24. 
320. Batrakova, E.V. and M.S. Kim, Development and regulation of exosome-based 
therapy products. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016. 8(5): p. 
744-57. 
321. Bryniarski, K., et al., Antigen-specific, antibody-coated, exosome-like nanovesicles 
deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact 
sensitivity. J Allergy Clin Immunol, 2013. 132(1): p. 170-81. 
322. Didiot, M.C., et al., Exosome-mediated Delivery of Hydrophobically Modified siRNA 
for Huntingtin mRNA Silencing. Mol Ther, 2016. 24(10): p. 1836-1847. 
323. Tian, Y., et al., A doxorubicin delivery platform using engineered natural membrane 
vesicle exosomes for targeted tumor therapy. Biomaterials, 2014. 35(7): p. 2383-90. 
324. Haney, M.J., et al., Exosomes as drug delivery vehicles for Parkinson's disease 
therapy. J Control Release, 2015. 207: p. 18-30. 
325. Wahlgren, J., et al., Plasma exosomes can deliver exogenous short interfering RNA to 
monocytes and lymphocytes. Nucleic Acids Res, 2012. 40(17): p. e130. 
326. Kooijmans, S.A., et al., Electroporation-induced siRNA precipitation obscures the 
efficiency of siRNA loading into extracellular vesicles. J Control Release, 2013. 
172(1): p. 229-38. 
327. Pascucci, L., et al., Paclitaxel is incorporated by mesenchymal stromal cells and 
released in exosomes that inhibit in vitro tumor growth: a new approach for drug 
delivery. J Control Release, 2014. 192: p. 262-70. 
328. Akao, Y., et al., Microvesicle-mediated RNA molecule delivery system using 
monocytes/macrophages. Mol Ther, 2011. 19(2): p. 395-9. 
329. Zhang, Y., et al., Secreted monocytic miR-150 enhances targeted endothelial cell 
migration. Mol Cell, 2010. 39(1): p. 133-44. 
330. Sugahara, K.N., et al., Tissue-penetrating delivery of compounds and nanoparticles 
into tumors. Cancer Cell, 2009. 16(6): p. 510-20. 
331. Kooijmans, S.A., et al., Display of GPI-anchored anti-EGFR nanobodies on 
extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles, 2016. 5: p. 
31053. 
332. Sterzenbach, U., et al., Engineered Exosomes as Vehicles for Biologically Active 
Proteins. Mol Ther, 2017. 25(6): p. 1269-1278. 
  67 
333. Maguire, C.A., et al., Microvesicle-associated AAV vector as a novel gene delivery 
system. Mol Ther, 2012. 20(5): p. 960-71. 
334. Sato, Y.T., et al., Engineering hybrid exosomes by membrane fusion with liposomes. 
Sci Rep, 2016. 6: p. 21933. 
335. Votteler, J., et al., Designed proteins induce the formation of nanocage-containing 
extracellular vesicles. Nature, 2016. 540(7632): p. 292-295. 
336. Yeo, R.W., et al., Mesenchymal stem cell: an efficient mass producer of exosomes for 
drug delivery. Adv Drug Deliv Rev, 2013. 65(3): p. 336-41. 
337. Kassis, I., et al., Mesenchymal stem cells (MSC) derived from mice with experimental 
autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological 
properties with MSC from healthy donors. Immunol Lett, 2013. 154(1-2): p. 70-6. 
338. Dragovic, R.A., et al., Sizing and phenotyping of cellular vesicles using Nanoparticle 
Tracking Analysis. Nanomedicine, 2011. 7(6): p. 780-8. 
339. Sokolova, V., et al., Characterisation of exosomes derived from human cells by 
nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B 
Biointerfaces, 2011. 87(1): p. 146-50. 
340. Copeland, S., et al., Acute inflammatory response to endotoxin in mice and humans. 
Clin Diagn Lab Immunol, 2005. 12(1): p. 60-7. 
341. Miller, S.D., W.J. Karpus, and T.S. Davidson, Experimental autoimmune 
encephalomyelitis in the mouse. Curr Protoc Immunol, 2010. Chapter 15: p. Unit 15 
1. 
342. Anderson, J.P., et al., Phosphorylation of Ser-129 is the dominant pathological 
modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol 
Chem, 2006. 281(40): p. 29739-52. 
343. Willis, G.R., S. Kourembanas, and S.A. Mitsialis, Therapeutic Applications of 
Extracellular Vesicles: Perspectives from Newborn Medicine. Methods Mol Biol, 
2017. 1660: p. 409-432. 
 
